5325232025-07-012025-09-305325232025-09-305325232025-03-315325232025-04-012025-09-305325232025-07-012025-09-30in-capmkt:OtherExpenses1Member5325232025-07-012025-09-30in-capmkt:OtherExpenses2Member5325232025-04-012025-09-30in-capmkt:OtherExpenses1Member5325232025-04-012025-09-30in-capmkt:OtherExpenses2Member5325232025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15325232025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15325232025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15325232025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15325232025-07-012025-09-30RelatedPartyTransactionDomain15325232025-06-30RelatedPartyTransactionDomain15325232025-09-30RelatedPartyTransactionDomain15325232025-07-012025-09-30RelatedPartyTransactionDomain25325232025-06-30RelatedPartyTransactionDomain25325232025-09-30RelatedPartyTransactionDomain25325232025-07-012025-09-30RelatedPartyTransactionDomain35325232025-06-30RelatedPartyTransactionDomain35325232025-09-30RelatedPartyTransactionDomain35325232025-07-012025-09-30RelatedPartyTransactionDomain45325232025-06-30RelatedPartyTransactionDomain45325232025-09-30RelatedPartyTransactionDomain45325232025-07-012025-09-30RelatedPartyTransactionDomain55325232025-06-30RelatedPartyTransactionDomain55325232025-09-30RelatedPartyTransactionDomain55325232025-07-012025-09-30RelatedPartyTransactionDomain65325232025-06-30RelatedPartyTransactionDomain65325232025-09-30RelatedPartyTransactionDomain65325232025-07-012025-09-30RelatedPartyTransactionDomain75325232025-06-30RelatedPartyTransactionDomain75325232025-09-30RelatedPartyTransactionDomain75325232025-07-012025-09-30RelatedPartyTransactionDomain85325232025-06-30RelatedPartyTransactionDomain85325232025-09-30RelatedPartyTransactionDomain85325232025-07-012025-09-30RelatedPartyTransactionDomain95325232025-06-30RelatedPartyTransactionDomain95325232025-09-30RelatedPartyTransactionDomain95325232025-07-012025-09-30RelatedPartyTransactionDomain105325232025-06-30RelatedPartyTransactionDomain105325232025-09-30RelatedPartyTransactionDomain105325232025-07-012025-09-30RelatedPartyTransactionDomain115325232025-06-30RelatedPartyTransactionDomain115325232025-09-30RelatedPartyTransactionDomain115325232025-07-012025-09-30RelatedPartyTransactionDomain125325232025-06-30RelatedPartyTransactionDomain125325232025-09-30RelatedPartyTransactionDomain125325232025-07-012025-09-30RelatedPartyTransactionDomain135325232025-06-30RelatedPartyTransactionDomain135325232025-09-30RelatedPartyTransactionDomain135325232025-07-012025-09-30RelatedPartyTransactionDomain145325232025-06-30RelatedPartyTransactionDomain145325232025-09-30RelatedPartyTransactionDomain145325232025-07-012025-09-30RelatedPartyTransactionDomain155325232025-06-30RelatedPartyTransactionDomain155325232025-09-30RelatedPartyTransactionDomain155325232025-07-012025-09-30RelatedPartyTransactionDomain165325232025-06-30RelatedPartyTransactionDomain165325232025-09-30RelatedPartyTransactionDomain165325232025-07-012025-09-30RelatedPartyTransactionDomain175325232025-06-30RelatedPartyTransactionDomain175325232025-09-30RelatedPartyTransactionDomain175325232025-07-012025-09-30RelatedPartyTransactionDomain185325232025-06-30RelatedPartyTransactionDomain185325232025-09-30RelatedPartyTransactionDomain185325232025-07-012025-09-30RelatedPartyTransactionDomain195325232025-06-30RelatedPartyTransactionDomain195325232025-09-30RelatedPartyTransactionDomain195325232025-07-012025-09-30RelatedPartyTransactionDomain205325232025-06-30RelatedPartyTransactionDomain205325232025-09-30RelatedPartyTransactionDomain205325232025-07-012025-09-30RelatedPartyTransactionDomain215325232025-06-30RelatedPartyTransactionDomain215325232025-09-30RelatedPartyTransactionDomain215325232025-07-012025-09-30RelatedPartyTransactionDomain225325232025-06-30RelatedPartyTransactionDomain225325232025-09-30RelatedPartyTransactionDomain225325232025-07-012025-09-30RelatedPartyTransactionDomain235325232025-06-30RelatedPartyTransactionDomain235325232025-09-30RelatedPartyTransactionDomain235325232025-07-012025-09-30RelatedPartyTransactionDomain245325232025-06-30RelatedPartyTransactionDomain245325232025-09-30RelatedPartyTransactionDomain245325232025-07-012025-09-30RelatedPartyTransactionDomain255325232025-06-30RelatedPartyTransactionDomain255325232025-09-30RelatedPartyTransactionDomain255325232025-07-012025-09-30RelatedPartyTransactionDomain265325232025-06-30RelatedPartyTransactionDomain265325232025-09-30RelatedPartyTransactionDomain265325232025-07-012025-09-30RelatedPartyTransactionDomain275325232025-06-30RelatedPartyTransactionDomain275325232025-09-30RelatedPartyTransactionDomain275325232025-07-012025-09-30RelatedPartyTransactionDomain285325232025-06-30RelatedPartyTransactionDomain285325232025-09-30RelatedPartyTransactionDomain285325232025-07-012025-09-30RelatedPartyTransactionDomain295325232025-06-30RelatedPartyTransactionDomain295325232025-09-30RelatedPartyTransactionDomain295325232025-07-012025-09-30RelatedPartyTransactionDomain305325232025-06-30RelatedPartyTransactionDomain305325232025-09-30RelatedPartyTransactionDomain305325232025-07-012025-09-30RelatedPartyTransactionDomain315325232025-06-30RelatedPartyTransactionDomain315325232025-09-30RelatedPartyTransactionDomain315325232025-07-012025-09-30RelatedPartyTransactionDomain325325232025-06-30RelatedPartyTransactionDomain325325232025-09-30RelatedPartyTransactionDomain325325232025-07-012025-09-30RelatedPartyTransactionDomain335325232025-06-30RelatedPartyTransactionDomain335325232025-09-30RelatedPartyTransactionDomain335325232025-07-012025-09-30RelatedPartyTransactionDomain345325232025-06-30RelatedPartyTransactionDomain345325232025-09-30RelatedPartyTransactionDomain345325232025-07-012025-09-30RelatedPartyTransactionDomain355325232025-06-30RelatedPartyTransactionDomain355325232025-09-30RelatedPartyTransactionDomain355325232025-07-012025-09-30RelatedPartyTransactionDomain365325232025-06-30RelatedPartyTransactionDomain365325232025-09-30RelatedPartyTransactionDomain365325232025-07-012025-09-30RelatedPartyTransactionDomain375325232025-06-30RelatedPartyTransactionDomain375325232025-09-30RelatedPartyTransactionDomain375325232025-07-012025-09-30RelatedPartyTransactionDomain385325232025-06-30RelatedPartyTransactionDomain385325232025-09-30RelatedPartyTransactionDomain385325232025-07-012025-09-30RelatedPartyTransactionDomain395325232025-06-30RelatedPartyTransactionDomain395325232025-09-30RelatedPartyTransactionDomain395325232025-07-012025-09-30RelatedPartyTransactionDomain405325232025-06-30RelatedPartyTransactionDomain405325232025-09-30RelatedPartyTransactionDomain405325232025-07-012025-09-30RelatedPartyTransactionDomain415325232025-06-30RelatedPartyTransactionDomain415325232025-09-30RelatedPartyTransactionDomain415325232025-07-012025-09-30RelatedPartyTransactionDomain425325232025-06-30RelatedPartyTransactionDomain425325232025-09-30RelatedPartyTransactionDomain425325232025-07-012025-09-30RelatedPartyTransactionDomain435325232025-06-30RelatedPartyTransactionDomain435325232025-09-30RelatedPartyTransactionDomain435325232025-07-012025-09-30RelatedPartyTransactionDomain445325232025-06-30RelatedPartyTransactionDomain445325232025-09-30RelatedPartyTransactionDomain445325232025-07-012025-09-30RelatedPartyTransactionDomain455325232025-06-30RelatedPartyTransactionDomain455325232025-09-30RelatedPartyTransactionDomain455325232025-07-012025-09-30RelatedPartyTransactionDomain465325232025-06-30RelatedPartyTransactionDomain465325232025-09-30RelatedPartyTransactionDomain465325232025-07-012025-09-30RelatedPartyTransactionDomain475325232025-06-30RelatedPartyTransactionDomain475325232025-09-30RelatedPartyTransactionDomain475325232025-07-012025-09-30RelatedPartyTransactionDomain485325232025-06-30RelatedPartyTransactionDomain485325232025-09-30RelatedPartyTransactionDomain485325232025-07-012025-09-30RelatedPartyTransactionDomain495325232025-06-30RelatedPartyTransactionDomain495325232025-09-30RelatedPartyTransactionDomain495325232025-07-012025-09-30RelatedPartyTransactionDomain505325232025-06-30RelatedPartyTransactionDomain505325232025-09-30RelatedPartyTransactionDomain505325232025-07-012025-09-30RelatedPartyTransactionDomain515325232025-06-30RelatedPartyTransactionDomain515325232025-09-30RelatedPartyTransactionDomain515325232025-07-012025-09-30RelatedPartyTransactionDomain525325232025-06-30RelatedPartyTransactionDomain525325232025-09-30RelatedPartyTransactionDomain525325232025-07-012025-09-30RelatedPartyTransactionDomain535325232025-06-30RelatedPartyTransactionDomain535325232025-09-30RelatedPartyTransactionDomain535325232025-07-012025-09-30RelatedPartyTransactionDomain545325232025-06-30RelatedPartyTransactionDomain545325232025-09-30RelatedPartyTransactionDomain545325232025-07-012025-09-30RelatedPartyTransactionDomain555325232025-06-30RelatedPartyTransactionDomain555325232025-09-30RelatedPartyTransactionDomain555325232025-07-012025-09-30RelatedPartyTransactionDomain565325232025-06-30RelatedPartyTransactionDomain565325232025-09-30RelatedPartyTransactionDomain565325232025-07-012025-09-30RelatedPartyTransactionDomain575325232025-06-30RelatedPartyTransactionDomain575325232025-09-30RelatedPartyTransactionDomain575325232025-07-012025-09-30RelatedPartyTransactionDomain585325232025-06-30RelatedPartyTransactionDomain585325232025-09-30RelatedPartyTransactionDomain585325232025-07-012025-09-30RelatedPartyTransactionDomain595325232025-06-30RelatedPartyTransactionDomain595325232025-09-30RelatedPartyTransactionDomain595325232025-07-012025-09-30RelatedPartyTransactionDomain605325232025-06-30RelatedPartyTransactionDomain605325232025-09-30RelatedPartyTransactionDomain605325232025-07-012025-09-30RelatedPartyTransactionDomain615325232025-06-30RelatedPartyTransactionDomain615325232025-09-30RelatedPartyTransactionDomain615325232025-07-012025-09-30RelatedPartyTransactionDomain625325232025-06-30RelatedPartyTransactionDomain625325232025-09-30RelatedPartyTransactionDomain625325232025-07-012025-09-30RelatedPartyTransactionDomain635325232025-06-30RelatedPartyTransactionDomain635325232025-09-30RelatedPartyTransactionDomain635325232025-07-012025-09-30RelatedPartyTransactionDomain645325232025-06-30RelatedPartyTransactionDomain645325232025-09-30RelatedPartyTransactionDomain645325232025-07-012025-09-30RelatedPartyTransactionDomain655325232025-06-30RelatedPartyTransactionDomain655325232025-09-30RelatedPartyTransactionDomain655325232025-07-012025-09-30RelatedPartyTransactionDomain665325232025-06-30RelatedPartyTransactionDomain665325232025-09-30RelatedPartyTransactionDomain665325232025-07-012025-09-30RelatedPartyTransactionDomain675325232025-06-30RelatedPartyTransactionDomain675325232025-09-30RelatedPartyTransactionDomain675325232025-07-012025-09-30RelatedPartyTransactionDomain685325232025-06-30RelatedPartyTransactionDomain685325232025-09-30RelatedPartyTransactionDomain685325232025-07-012025-09-30RelatedPartyTransactionDomain695325232025-06-30RelatedPartyTransactionDomain695325232025-09-30RelatedPartyTransactionDomain695325232025-07-012025-09-30RelatedPartyTransactionDomain705325232025-06-30RelatedPartyTransactionDomain705325232025-09-30RelatedPartyTransactionDomain705325232025-07-012025-09-30RelatedPartyTransactionDomain715325232025-06-30RelatedPartyTransactionDomain715325232025-09-30RelatedPartyTransactionDomain715325232025-07-012025-09-30RelatedPartyTransactionDomain725325232025-06-30RelatedPartyTransactionDomain725325232025-09-30RelatedPartyTransactionDomain725325232025-07-012025-09-30RelatedPartyTransactionDomain735325232025-06-30RelatedPartyTransactionDomain735325232025-09-30RelatedPartyTransactionDomain735325232025-07-012025-09-30RelatedPartyTransactionDomain745325232025-06-30RelatedPartyTransactionDomain745325232025-09-30RelatedPartyTransactionDomain745325232025-07-012025-09-30RelatedPartyTransactionDomain755325232025-06-30RelatedPartyTransactionDomain755325232025-09-30RelatedPartyTransactionDomain755325232025-07-012025-09-30RelatedPartyTransactionDomain765325232025-06-30RelatedPartyTransactionDomain765325232025-09-30RelatedPartyTransactionDomain765325232025-07-012025-09-30RelatedPartyTransactionDomain775325232025-06-30RelatedPartyTransactionDomain775325232025-09-30RelatedPartyTransactionDomain775325232025-07-012025-09-30RelatedPartyTransactionDomain785325232025-06-30RelatedPartyTransactionDomain785325232025-09-30RelatedPartyTransactionDomain785325232025-07-012025-09-30RelatedPartyTransactionDomain795325232025-06-30RelatedPartyTransactionDomain795325232025-09-30RelatedPartyTransactionDomain795325232025-07-012025-09-30RelatedPartyTransactionDomain805325232025-06-30RelatedPartyTransactionDomain805325232025-09-30RelatedPartyTransactionDomain805325232025-07-012025-09-30RelatedPartyTransactionDomain815325232025-06-30RelatedPartyTransactionDomain815325232025-09-30RelatedPartyTransactionDomain815325232025-07-012025-09-30RelatedPartyTransactionDomain825325232025-06-30RelatedPartyTransactionDomain825325232025-09-30RelatedPartyTransactionDomain825325232025-07-012025-09-30RelatedPartyTransactionDomain835325232025-06-30RelatedPartyTransactionDomain835325232025-09-30RelatedPartyTransactionDomain835325232025-07-012025-09-30RelatedPartyTransactionDomain845325232025-06-30RelatedPartyTransactionDomain845325232025-09-30RelatedPartyTransactionDomain845325232025-07-012025-09-30RelatedPartyTransactionDomain855325232025-06-30RelatedPartyTransactionDomain855325232025-09-30RelatedPartyTransactionDomain855325232025-07-012025-09-30RelatedPartyTransactionDomain865325232025-06-30RelatedPartyTransactionDomain865325232025-09-30RelatedPartyTransactionDomain865325232025-07-012025-09-30RelatedPartyTransactionDomain875325232025-06-30RelatedPartyTransactionDomain875325232025-09-30RelatedPartyTransactionDomain875325232025-07-012025-09-30RelatedPartyTransactionDomain885325232025-06-30RelatedPartyTransactionDomain885325232025-09-30RelatedPartyTransactionDomain885325232025-07-012025-09-30RelatedPartyTransactionDomain895325232025-06-30RelatedPartyTransactionDomain895325232025-09-30RelatedPartyTransactionDomain895325232025-07-012025-09-30RelatedPartyTransactionDomain905325232025-06-30RelatedPartyTransactionDomain905325232025-09-30RelatedPartyTransactionDomain905325232025-07-012025-09-30RelatedPartyTransactionDomain915325232025-06-30RelatedPartyTransactionDomain915325232025-09-30RelatedPartyTransactionDomain915325232025-07-012025-09-30RelatedPartyTransactionDomain925325232025-06-30RelatedPartyTransactionDomain925325232025-09-30RelatedPartyTransactionDomain925325232025-07-012025-09-30RelatedPartyTransactionDomain935325232025-06-30RelatedPartyTransactionDomain935325232025-09-30RelatedPartyTransactionDomain935325232025-07-012025-09-30RelatedPartyTransactionDomain945325232025-06-30RelatedPartyTransactionDomain945325232025-09-30RelatedPartyTransactionDomain945325232025-07-012025-09-30RelatedPartyTransactionDomain955325232025-06-30RelatedPartyTransactionDomain955325232025-09-30RelatedPartyTransactionDomain955325232025-07-012025-09-30RelatedPartyTransactionDomain965325232025-06-30RelatedPartyTransactionDomain965325232025-09-30RelatedPartyTransactionDomain965325232025-07-012025-09-30RelatedPartyTransactionDomain975325232025-06-30RelatedPartyTransactionDomain975325232025-09-30RelatedPartyTransactionDomain975325232025-07-012025-09-30RelatedPartyTransactionDomain985325232025-06-30RelatedPartyTransactionDomain985325232025-09-30RelatedPartyTransactionDomain985325232025-07-012025-09-30RelatedPartyTransactionDomain995325232025-06-30RelatedPartyTransactionDomain995325232025-09-30RelatedPartyTransactionDomain995325232025-07-012025-09-30RelatedPartyTransactionDomain1005325232025-06-30RelatedPartyTransactionDomain1005325232025-09-30RelatedPartyTransactionDomain1005325232025-07-012025-09-30RelatedPartyTransactionDomain1015325232025-06-30RelatedPartyTransactionDomain1015325232025-09-30RelatedPartyTransactionDomain1015325232025-07-012025-09-30RelatedPartyTransactionDomain1025325232025-06-30RelatedPartyTransactionDomain1025325232025-09-30RelatedPartyTransactionDomain1025325232025-07-012025-09-30RelatedPartyTransactionDomain1035325232025-06-30RelatedPartyTransactionDomain1035325232025-09-30RelatedPartyTransactionDomain1035325232025-07-012025-09-30RelatedPartyTransactionDomain1045325232025-06-30RelatedPartyTransactionDomain1045325232025-09-30RelatedPartyTransactionDomain1045325232025-07-012025-09-30RelatedPartyTransactionDomain1055325232025-06-30RelatedPartyTransactionDomain1055325232025-09-30RelatedPartyTransactionDomain1055325232025-07-012025-09-30RelatedPartyTransactionDomain1065325232025-06-30RelatedPartyTransactionDomain1065325232025-09-30RelatedPartyTransactionDomain1065325232025-07-012025-09-30RelatedPartyTransactionDomain1075325232025-06-30RelatedPartyTransactionDomain1075325232025-09-30RelatedPartyTransactionDomain1075325232025-07-012025-09-30RelatedPartyTransactionDomain1085325232025-06-30RelatedPartyTransactionDomain1085325232025-09-30RelatedPartyTransactionDomain1085325232025-07-012025-09-30RelatedPartyTransactionDomain1095325232025-06-30RelatedPartyTransactionDomain1095325232025-09-30RelatedPartyTransactionDomain1095325232025-07-012025-09-30RelatedPartyTransactionDomain1105325232025-06-30RelatedPartyTransactionDomain1105325232025-09-30RelatedPartyTransactionDomain1105325232025-07-012025-09-30RelatedPartyTransactionDomain1115325232025-06-30RelatedPartyTransactionDomain1115325232025-09-30RelatedPartyTransactionDomain1115325232025-07-012025-09-30RelatedPartyTransactionDomain1125325232025-06-30RelatedPartyTransactionDomain1125325232025-09-30RelatedPartyTransactionDomain1125325232025-07-012025-09-30RelatedPartyTransactionDomain1135325232025-06-30RelatedPartyTransactionDomain1135325232025-09-30RelatedPartyTransactionDomain1135325232025-07-012025-09-30RelatedPartyTransactionDomain1145325232025-06-30RelatedPartyTransactionDomain1145325232025-09-30RelatedPartyTransactionDomain1145325232025-07-012025-09-30RelatedPartyTransactionDomain1155325232025-06-30RelatedPartyTransactionDomain1155325232025-09-30RelatedPartyTransactionDomain1155325232025-07-012025-09-30RelatedPartyTransactionDomain1165325232025-06-30RelatedPartyTransactionDomain1165325232025-09-30RelatedPartyTransactionDomain1165325232025-07-012025-09-30RelatedPartyTransactionDomain1175325232025-06-30RelatedPartyTransactionDomain1175325232025-09-30RelatedPartyTransactionDomain1175325232025-07-012025-09-30RelatedPartyTransactionDomain1185325232025-06-30RelatedPartyTransactionDomain1185325232025-09-30RelatedPartyTransactionDomain1185325232025-07-012025-09-30RelatedPartyTransactionDomain1195325232025-06-30RelatedPartyTransactionDomain1195325232025-09-30RelatedPartyTransactionDomain1195325232025-07-012025-09-30RelatedPartyTransactionDomain1205325232025-06-30RelatedPartyTransactionDomain1205325232025-09-30RelatedPartyTransactionDomain1205325232025-07-012025-09-30RelatedPartyTransactionDomain1215325232025-06-30RelatedPartyTransactionDomain1215325232025-09-30RelatedPartyTransactionDomain1215325232025-07-012025-09-30RelatedPartyTransactionDomain1225325232025-06-30RelatedPartyTransactionDomain1225325232025-09-30RelatedPartyTransactionDomain1225325232025-07-012025-09-30RelatedPartyTransactionDomain1235325232025-06-30RelatedPartyTransactionDomain1235325232025-09-30RelatedPartyTransactionDomain1235325232025-07-012025-09-30RelatedPartyTransactionDomain1245325232025-06-30RelatedPartyTransactionDomain1245325232025-09-30RelatedPartyTransactionDomain1245325232025-07-012025-09-30RelatedPartyTransactionDomain1255325232025-06-30RelatedPartyTransactionDomain1255325232025-09-30RelatedPartyTransactionDomain1255325232025-07-012025-09-30RelatedPartyTransactionDomain1265325232025-06-30RelatedPartyTransactionDomain1265325232025-09-30RelatedPartyTransactionDomain1265325232025-07-012025-09-30RelatedPartyTransactionDomain1275325232025-06-30RelatedPartyTransactionDomain1275325232025-09-30RelatedPartyTransactionDomain1275325232025-07-012025-09-30RelatedPartyTransactionDomain1285325232025-06-30RelatedPartyTransactionDomain1285325232025-09-30RelatedPartyTransactionDomain1285325232025-07-012025-09-30RelatedPartyTransactionDomain1295325232025-06-30RelatedPartyTransactionDomain1295325232025-09-30RelatedPartyTransactionDomain1295325232025-07-012025-09-30RelatedPartyTransactionDomain1305325232025-06-30RelatedPartyTransactionDomain1305325232025-09-30RelatedPartyTransactionDomain1305325232025-07-012025-09-30RelatedPartyTransactionDomain1315325232025-06-30RelatedPartyTransactionDomain1315325232025-09-30RelatedPartyTransactionDomain1315325232025-07-012025-09-30RelatedPartyTransactionDomain1325325232025-06-30RelatedPartyTransactionDomain1325325232025-09-30RelatedPartyTransactionDomain1325325232025-07-012025-09-30RelatedPartyTransactionDomain1335325232025-06-30RelatedPartyTransactionDomain1335325232025-09-30RelatedPartyTransactionDomain1335325232025-07-012025-09-30RelatedPartyTransactionDomain1345325232025-06-30RelatedPartyTransactionDomain1345325232025-09-30RelatedPartyTransactionDomain1345325232025-07-012025-09-30RelatedPartyTransactionDomain1355325232025-06-30RelatedPartyTransactionDomain1355325232025-09-30RelatedPartyTransactionDomain1355325232025-07-012025-09-30RelatedPartyTransactionDomain1365325232025-06-30RelatedPartyTransactionDomain1365325232025-09-30RelatedPartyTransactionDomain1365325232025-07-012025-09-30RelatedPartyTransactionDomain1375325232025-06-30RelatedPartyTransactionDomain1375325232025-09-30RelatedPartyTransactionDomain1375325232025-07-012025-09-30RelatedPartyTransactionDomain1385325232025-06-30RelatedPartyTransactionDomain1385325232025-09-30RelatedPartyTransactionDomain1385325232025-07-012025-09-30RelatedPartyTransactionDomain1395325232025-06-30RelatedPartyTransactionDomain1395325232025-09-30RelatedPartyTransactionDomain1395325232025-07-012025-09-30RelatedPartyTransactionDomain1405325232025-06-30RelatedPartyTransactionDomain1405325232025-09-30RelatedPartyTransactionDomain1405325232025-07-012025-09-30RelatedPartyTransactionDomain1415325232025-06-30RelatedPartyTransactionDomain1415325232025-09-30RelatedPartyTransactionDomain1415325232025-07-012025-09-30RelatedPartyTransactionDomain1425325232025-06-30RelatedPartyTransactionDomain1425325232025-09-30RelatedPartyTransactionDomain1425325232025-07-012025-09-30RelatedPartyTransactionDomain1435325232025-06-30RelatedPartyTransactionDomain1435325232025-09-30RelatedPartyTransactionDomain1435325232025-07-012025-09-30RelatedPartyTransactionDomain1445325232025-06-30RelatedPartyTransactionDomain1445325232025-09-30RelatedPartyTransactionDomain1445325232025-07-012025-09-30RelatedPartyTransactionDomain1455325232025-06-30RelatedPartyTransactionDomain1455325232025-09-30RelatedPartyTransactionDomain1455325232025-07-012025-09-30RelatedPartyTransactionDomain1465325232025-06-30RelatedPartyTransactionDomain1465325232025-09-30RelatedPartyTransactionDomain1465325232025-07-012025-09-30RelatedPartyTransactionDomain1475325232025-06-30RelatedPartyTransactionDomain1475325232025-09-30RelatedPartyTransactionDomain1475325232025-07-012025-09-30RelatedPartyTransactionDomain1485325232025-06-30RelatedPartyTransactionDomain1485325232025-09-30RelatedPartyTransactionDomain1485325232025-07-012025-09-30RelatedPartyTransactionDomain1495325232025-06-30RelatedPartyTransactionDomain1495325232025-09-30RelatedPartyTransactionDomain1495325232025-07-012025-09-30RelatedPartyTransactionDomain1505325232025-06-30RelatedPartyTransactionDomain1505325232025-09-30RelatedPartyTransactionDomain1505325232025-07-012025-09-30RelatedPartyTransactionDomain1515325232025-06-30RelatedPartyTransactionDomain1515325232025-09-30RelatedPartyTransactionDomain1515325232025-07-012025-09-30RelatedPartyTransactionDomain1525325232025-06-30RelatedPartyTransactionDomain1525325232025-09-30RelatedPartyTransactionDomain1525325232025-07-012025-09-30RelatedPartyTransactionDomain1535325232025-06-30RelatedPartyTransactionDomain1535325232025-09-30RelatedPartyTransactionDomain1535325232025-07-012025-09-30RelatedPartyTransactionDomain1545325232025-06-30RelatedPartyTransactionDomain1545325232025-09-30RelatedPartyTransactionDomain1545325232025-07-012025-09-30RelatedPartyTransactionDomain1555325232025-06-30RelatedPartyTransactionDomain1555325232025-09-30RelatedPartyTransactionDomain1555325232025-07-012025-09-30RelatedPartyTransactionDomain1565325232025-06-30RelatedPartyTransactionDomain1565325232025-09-30RelatedPartyTransactionDomain1565325232025-07-012025-09-30RelatedPartyTransactionDomain1575325232025-06-30RelatedPartyTransactionDomain1575325232025-09-30RelatedPartyTransactionDomain1575325232025-07-012025-09-30RelatedPartyTransactionDomain1585325232025-06-30RelatedPartyTransactionDomain1585325232025-09-30RelatedPartyTransactionDomain1585325232025-07-012025-09-30RelatedPartyTransactionDomain1595325232025-06-30RelatedPartyTransactionDomain1595325232025-09-30RelatedPartyTransactionDomain1595325232025-07-012025-09-30RelatedPartyTransactionDomain1605325232025-06-30RelatedPartyTransactionDomain1605325232025-09-30RelatedPartyTransactionDomain1605325232025-07-012025-09-30RelatedPartyTransactionDomain1615325232025-06-30RelatedPartyTransactionDomain1615325232025-09-30RelatedPartyTransactionDomain1615325232025-07-012025-09-30RelatedPartyTransactionDomain1625325232025-06-30RelatedPartyTransactionDomain1625325232025-09-30RelatedPartyTransactionDomain1625325232025-07-012025-09-30RelatedPartyTransactionDomain1635325232025-06-30RelatedPartyTransactionDomain1635325232025-09-30RelatedPartyTransactionDomain1635325232025-07-012025-09-30RelatedPartyTransactionDomain1645325232025-06-30RelatedPartyTransactionDomain1645325232025-09-30RelatedPartyTransactionDomain1645325232025-07-012025-09-30RelatedPartyTransactionDomain1655325232025-06-30RelatedPartyTransactionDomain1655325232025-09-30RelatedPartyTransactionDomain1655325232025-07-012025-09-30RelatedPartyTransactionDomain1665325232025-06-30RelatedPartyTransactionDomain1665325232025-09-30RelatedPartyTransactionDomain1665325232025-07-012025-09-30RelatedPartyTransactionDomain1675325232025-06-30RelatedPartyTransactionDomain1675325232025-09-30RelatedPartyTransactionDomain1675325232025-07-012025-09-30RelatedPartyTransactionDomain1685325232025-06-30RelatedPartyTransactionDomain1685325232025-09-30RelatedPartyTransactionDomain1685325232025-07-012025-09-30RelatedPartyTransactionDomain1695325232025-06-30RelatedPartyTransactionDomain1695325232025-09-30RelatedPartyTransactionDomain1695325232025-07-012025-09-30RelatedPartyTransactionDomain1705325232025-06-30RelatedPartyTransactionDomain1705325232025-09-30RelatedPartyTransactionDomain1705325232025-07-012025-09-30RelatedPartyTransactionDomain1715325232025-06-30RelatedPartyTransactionDomain1715325232025-09-30RelatedPartyTransactionDomain1715325232025-07-012025-09-30RelatedPartyTransactionDomain1725325232025-06-30RelatedPartyTransactionDomain1725325232025-09-30RelatedPartyTransactionDomain1725325232025-07-012025-09-30RelatedPartyTransactionDomain1735325232025-06-30RelatedPartyTransactionDomain1735325232025-09-30RelatedPartyTransactionDomain1735325232025-07-012025-09-30RelatedPartyTransactionDomain1745325232025-06-30RelatedPartyTransactionDomain1745325232025-09-30RelatedPartyTransactionDomain1745325232025-07-012025-09-30RelatedPartyTransactionDomain1755325232025-06-30RelatedPartyTransactionDomain1755325232025-09-30RelatedPartyTransactionDomain1755325232025-07-012025-09-30RelatedPartyTransactionDomain1765325232025-06-30RelatedPartyTransactionDomain1765325232025-09-30RelatedPartyTransactionDomain1765325232025-07-012025-09-30RelatedPartyTransactionDomain1775325232025-06-30RelatedPartyTransactionDomain1775325232025-09-30RelatedPartyTransactionDomain1775325232025-07-012025-09-30RelatedPartyTransactionDomain1785325232025-06-30RelatedPartyTransactionDomain1785325232025-09-30RelatedPartyTransactionDomain1785325232025-07-012025-09-30RelatedPartyTransactionDomain1795325232025-06-30RelatedPartyTransactionDomain1795325232025-09-30RelatedPartyTransactionDomain1795325232025-07-012025-09-30RelatedPartyTransactionDomain1805325232025-06-30RelatedPartyTransactionDomain1805325232025-09-30RelatedPartyTransactionDomain1805325232025-07-012025-09-30RelatedPartyTransactionDomain1815325232025-06-30RelatedPartyTransactionDomain1815325232025-09-30RelatedPartyTransactionDomain1815325232025-07-012025-09-30RelatedPartyTransactionDomain1825325232025-06-30RelatedPartyTransactionDomain1825325232025-09-30RelatedPartyTransactionDomain1825325232025-07-012025-09-30RelatedPartyTransactionDomain1835325232025-06-30RelatedPartyTransactionDomain1835325232025-09-30RelatedPartyTransactionDomain1835325232025-07-012025-09-30RelatedPartyTransactionDomain1845325232025-06-30RelatedPartyTransactionDomain1845325232025-09-30RelatedPartyTransactionDomain1845325232025-07-012025-09-30RelatedPartyTransactionDomain1855325232025-06-30RelatedPartyTransactionDomain1855325232025-09-30RelatedPartyTransactionDomain1855325232025-07-012025-09-30RelatedPartyTransactionDomain1865325232025-06-30RelatedPartyTransactionDomain1865325232025-09-30RelatedPartyTransactionDomain1865325232025-07-012025-09-30RelatedPartyTransactionDomain1875325232025-06-30RelatedPartyTransactionDomain1875325232025-09-30RelatedPartyTransactionDomain1875325232025-07-012025-09-30RelatedPartyTransactionDomain1885325232025-06-30RelatedPartyTransactionDomain1885325232025-09-30RelatedPartyTransactionDomain1885325232025-07-012025-09-30RelatedPartyTransactionDomain1895325232025-06-30RelatedPartyTransactionDomain1895325232025-09-30RelatedPartyTransactionDomain1895325232025-07-012025-09-30RelatedPartyTransactionDomain1905325232025-06-30RelatedPartyTransactionDomain1905325232025-09-30RelatedPartyTransactionDomain1905325232025-07-012025-09-30RelatedPartyTransactionDomain1915325232025-06-30RelatedPartyTransactionDomain1915325232025-09-30RelatedPartyTransactionDomain1915325232025-07-012025-09-30RelatedPartyTransactionDomain1925325232025-06-30RelatedPartyTransactionDomain1925325232025-09-30RelatedPartyTransactionDomain1925325232025-07-012025-09-30RelatedPartyTransactionDomain1935325232025-06-30RelatedPartyTransactionDomain1935325232025-09-30RelatedPartyTransactionDomain1935325232025-07-012025-09-30RelatedPartyTransactionDomain1945325232025-06-30RelatedPartyTransactionDomain1945325232025-09-30RelatedPartyTransactionDomain1945325232025-07-012025-09-30RelatedPartyTransactionDomain1955325232025-06-30RelatedPartyTransactionDomain1955325232025-09-30RelatedPartyTransactionDomain1955325232025-07-012025-09-30RelatedPartyTransactionDomain1965325232025-06-30RelatedPartyTransactionDomain1965325232025-09-30RelatedPartyTransactionDomain1965325232025-07-012025-09-30RelatedPartyTransactionDomain1975325232025-06-30RelatedPartyTransactionDomain1975325232025-09-30RelatedPartyTransactionDomain1975325232025-07-012025-09-30RelatedPartyTransactionDomain1985325232025-06-30RelatedPartyTransactionDomain1985325232025-09-30RelatedPartyTransactionDomain1985325232025-07-012025-09-30RelatedPartyTransactionDomain1995325232025-06-30RelatedPartyTransactionDomain1995325232025-09-30RelatedPartyTransactionDomain1995325232025-07-012025-09-30RelatedPartyTransactionDomain2005325232025-06-30RelatedPartyTransactionDomain2005325232025-09-30RelatedPartyTransactionDomain2005325232025-07-012025-09-30RelatedPartyTransactionDomain2015325232025-06-30RelatedPartyTransactionDomain2015325232025-09-30RelatedPartyTransactionDomain2015325232025-07-012025-09-30RelatedPartyTransactionDomain2025325232025-06-30RelatedPartyTransactionDomain2025325232025-09-30RelatedPartyTransactionDomain2025325232025-07-012025-09-30RelatedPartyTransactionDomain2035325232025-06-30RelatedPartyTransactionDomain2035325232025-09-30RelatedPartyTransactionDomain2035325232025-07-012025-09-30RelatedPartyTransactionDomain2045325232025-06-30RelatedPartyTransactionDomain2045325232025-09-30RelatedPartyTransactionDomain2045325232025-07-012025-09-30RelatedPartyTransactionDomain2055325232025-06-30RelatedPartyTransactionDomain2055325232025-09-30RelatedPartyTransactionDomain2055325232025-07-012025-09-30RelatedPartyTransactionDomain2065325232025-06-30RelatedPartyTransactionDomain2065325232025-09-30RelatedPartyTransactionDomain2065325232025-07-012025-09-30RelatedPartyTransactionDomain2075325232025-06-30RelatedPartyTransactionDomain2075325232025-09-30RelatedPartyTransactionDomain2075325232025-07-012025-09-30RelatedPartyTransactionDomain2085325232025-06-30RelatedPartyTransactionDomain2085325232025-09-30RelatedPartyTransactionDomain2085325232025-07-012025-09-30RelatedPartyTransactionDomain2095325232025-06-30RelatedPartyTransactionDomain2095325232025-09-30RelatedPartyTransactionDomain2095325232025-07-012025-09-30RelatedPartyTransactionDomain2105325232025-06-30RelatedPartyTransactionDomain2105325232025-09-30RelatedPartyTransactionDomain2105325232025-07-012025-09-30RelatedPartyTransactionDomain2115325232025-06-30RelatedPartyTransactionDomain2115325232025-09-30RelatedPartyTransactionDomain2115325232025-07-012025-09-30RelatedPartyTransactionDomain2125325232025-06-30RelatedPartyTransactionDomain2125325232025-09-30RelatedPartyTransactionDomain2125325232025-07-012025-09-30RelatedPartyTransactionDomain2135325232025-06-30RelatedPartyTransactionDomain2135325232025-09-30RelatedPartyTransactionDomain2135325232025-07-012025-09-30RelatedPartyTransactionDomain2145325232025-06-30RelatedPartyTransactionDomain2145325232025-09-30RelatedPartyTransactionDomain2145325232025-07-012025-09-30RelatedPartyTransactionDomain2155325232025-06-30RelatedPartyTransactionDomain2155325232025-09-30RelatedPartyTransactionDomain2155325232025-07-012025-09-30RelatedPartyTransactionDomain2165325232025-06-30RelatedPartyTransactionDomain2165325232025-09-30RelatedPartyTransactionDomain2165325232025-07-012025-09-30RelatedPartyTransactionDomain2175325232025-06-30RelatedPartyTransactionDomain2175325232025-09-30RelatedPartyTransactionDomain2175325232025-07-012025-09-30RelatedPartyTransactionDomain2185325232025-06-30RelatedPartyTransactionDomain2185325232025-09-30RelatedPartyTransactionDomain2185325232025-07-012025-09-30RelatedPartyTransactionDomain2195325232025-06-30RelatedPartyTransactionDomain2195325232025-09-30RelatedPartyTransactionDomain2195325232025-07-012025-09-30RelatedPartyTransactionDomain2205325232025-06-30RelatedPartyTransactionDomain2205325232025-09-30RelatedPartyTransactionDomain2205325232025-07-012025-09-30RelatedPartyTransactionDomain2215325232025-06-30RelatedPartyTransactionDomain2215325232025-09-30RelatedPartyTransactionDomain2215325232025-07-012025-09-30RelatedPartyTransactionDomain2225325232025-06-30RelatedPartyTransactionDomain2225325232025-09-30RelatedPartyTransactionDomain2225325232025-07-012025-09-30RelatedPartyTransactionDomain2235325232025-06-30RelatedPartyTransactionDomain2235325232025-09-30RelatedPartyTransactionDomain2235325232025-07-012025-09-30RelatedPartyTransactionDomain2245325232025-06-30RelatedPartyTransactionDomain2245325232025-09-30RelatedPartyTransactionDomain2245325232025-07-012025-09-30RelatedPartyTransactionDomain2255325232025-06-30RelatedPartyTransactionDomain2255325232025-09-30RelatedPartyTransactionDomain2255325232025-07-012025-09-30RelatedPartyTransactionDomain2265325232025-06-30RelatedPartyTransactionDomain2265325232025-09-30RelatedPartyTransactionDomain2265325232025-07-012025-09-30RelatedPartyTransactionDomain2275325232025-06-30RelatedPartyTransactionDomain2275325232025-09-30RelatedPartyTransactionDomain2275325232025-07-012025-09-30RelatedPartyTransactionDomain2285325232025-06-30RelatedPartyTransactionDomain2285325232025-09-30RelatedPartyTransactionDomain2285325232025-07-012025-09-30RelatedPartyTransactionDomain2295325232025-06-30RelatedPartyTransactionDomain2295325232025-09-30RelatedPartyTransactionDomain2295325232025-07-012025-09-30RelatedPartyTransactionDomain2305325232025-06-30RelatedPartyTransactionDomain2305325232025-09-30RelatedPartyTransactionDomain2305325232025-07-012025-09-30RelatedPartyTransactionDomain2315325232025-06-30RelatedPartyTransactionDomain2315325232025-09-30RelatedPartyTransactionDomain2315325232025-07-012025-09-30RelatedPartyTransactionDomain2325325232025-06-30RelatedPartyTransactionDomain2325325232025-09-30RelatedPartyTransactionDomain2325325232025-07-012025-09-30RelatedPartyTransactionDomain2335325232025-06-30RelatedPartyTransactionDomain2335325232025-09-30RelatedPartyTransactionDomain2335325232025-07-012025-09-30RelatedPartyTransactionDomain2345325232025-06-30RelatedPartyTransactionDomain2345325232025-09-30RelatedPartyTransactionDomain2345325232025-07-012025-09-30RelatedPartyTransactionDomain2355325232025-06-30RelatedPartyTransactionDomain2355325232025-09-30RelatedPartyTransactionDomain2355325232025-07-012025-09-30RelatedPartyTransactionDomain2365325232025-06-30RelatedPartyTransactionDomain2365325232025-09-30RelatedPartyTransactionDomain2365325232025-07-012025-09-30RelatedPartyTransactionDomain2375325232025-06-30RelatedPartyTransactionDomain2375325232025-09-30RelatedPartyTransactionDomain2375325232025-07-012025-09-30RelatedPartyTransactionDomain2385325232025-06-30RelatedPartyTransactionDomain2385325232025-09-30RelatedPartyTransactionDomain2385325232025-07-012025-09-30RelatedPartyTransactionDomain2395325232025-06-30RelatedPartyTransactionDomain2395325232025-09-30RelatedPartyTransactionDomain2395325232025-07-012025-09-30RelatedPartyTransactionDomain2405325232025-06-30RelatedPartyTransactionDomain2405325232025-09-30RelatedPartyTransactionDomain2405325232025-07-012025-09-30RelatedPartyTransactionDomain2415325232025-06-30RelatedPartyTransactionDomain2415325232025-09-30RelatedPartyTransactionDomain2415325232025-07-012025-09-30RelatedPartyTransactionDomain2425325232025-06-30RelatedPartyTransactionDomain2425325232025-09-30RelatedPartyTransactionDomain2425325232025-07-012025-09-30RelatedPartyTransactionDomain2435325232025-06-30RelatedPartyTransactionDomain2435325232025-09-30RelatedPartyTransactionDomain2435325232025-07-012025-09-30RelatedPartyTransactionDomain2445325232025-06-30RelatedPartyTransactionDomain2445325232025-09-30RelatedPartyTransactionDomain2445325232025-07-012025-09-30RelatedPartyTransactionDomain2455325232025-06-30RelatedPartyTransactionDomain2455325232025-09-30RelatedPartyTransactionDomain2455325232025-07-012025-09-30RelatedPartyTransactionDomain2465325232025-06-30RelatedPartyTransactionDomain2465325232025-09-30RelatedPartyTransactionDomain2465325232025-07-012025-09-30RelatedPartyTransactionDomain2475325232025-06-30RelatedPartyTransactionDomain2475325232025-09-30RelatedPartyTransactionDomain2475325232025-07-012025-09-30RelatedPartyTransactionDomain2485325232025-06-30RelatedPartyTransactionDomain2485325232025-09-30RelatedPartyTransactionDomain2485325232025-07-012025-09-30RelatedPartyTransactionDomain2495325232025-06-30RelatedPartyTransactionDomain2495325232025-09-30RelatedPartyTransactionDomain2495325232025-07-012025-09-30RelatedPartyTransactionDomain2505325232025-06-30RelatedPartyTransactionDomain2505325232025-09-30RelatedPartyTransactionDomain2505325232025-07-012025-09-30RelatedPartyTransactionDomain2515325232025-06-30RelatedPartyTransactionDomain2515325232025-09-30RelatedPartyTransactionDomain2515325232025-07-012025-09-30RelatedPartyTransactionDomain2525325232025-06-30RelatedPartyTransactionDomain2525325232025-09-30RelatedPartyTransactionDomain2525325232025-07-012025-09-30RelatedPartyTransactionDomain2535325232025-06-30RelatedPartyTransactionDomain2535325232025-09-30RelatedPartyTransactionDomain2535325232025-07-012025-09-30RelatedPartyTransactionDomain2545325232025-06-30RelatedPartyTransactionDomain2545325232025-09-30RelatedPartyTransactionDomain2545325232025-09-30Statement15325232025-07-012025-09-30Statement15325232025-09-30StatementDynamic1I1Statement15325232025-09-30StatementDynamic1I2Statement15325232025-09-30StatementDynamic1I3Statement15325232025-09-30StatementDynamic1I4Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares532523BIOCONNOTLISTEDINE376G01013BIOCON LIMITEDMain BoardEquity2025-04-012026-03-312025-11-112025-10-06INRMillionsQuarterlySecond quarterSingle segmentPharmaceutical2025-11-1116:30:002025-11-1117:45:00trueCash Flow IndirectNot applicabletruetrueNANAfalsetrue2025-01-30https://www.biocon.com/docs/Policy-on-Related-Party-Transactions.pdftrue1falseNo default on Loans and Debt Securities2025-07-012025-09-30UnauditedStandalone5833000000133800000071710000003207000000241000000-784000000126200000067200000033800000013780000006314000000857000000085700000032000000116000000148000000070900000000007090000009000000718000000668500000050.550.55000.550.550001. The unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 11, 2025. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. <BR> <BR> 2. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <BR> <BR> 3. The consolidated financial results include the financial results of the Company and its subsidiaries as follows: <BR> <BR> i. Syngene International Limited (‘’Syngene’’) <BR> ii. Biocon Biologics Limited (“BBL”) <BR> iii. Biocon Pharma Limited (“BPL”) <BR> iv. Biocon Academy <BR> v. Biocon SA <BR> vi. Biocon SDN. BHD <BR> vii. Biocon FZ LLC <BR> viii. Biocon Biologics International Limited (formerly known as Biocon Biologics UK Limited) <BR> ix. Biocon Pharma Inc. <BR> x. Biocon Biologics Healthcare Malaysia SDN. BHD <BR> xi. Biocon Pharma Ireland Limited <BR> xii. Biocon Pharma UK Limited <BR> xiii. Biocon Biosphere Limited <BR> xiv. Biocon Biologics Inc. <BR> xv. Biocon Biologics Do Brasil Ltda <BR> xvi. Biocon Biologics FZ-LLC <BR> xvii. Biocon Pharma Malta Limited <BR> xviii. Biocon Pharma Malta I Limited <BR> xix. Syngene USA Inc. <BR> xx. Syngene Manufacturing Solutions Limited <BR> xxi. Syngene Scientific Solutions Limited <BR> xxii. Biosimilar Collaborations Ireland Limited <BR> xxiii. Biocon Biologics UK PLC (formerly known as Biosimilars Newco Limited) <BR> xxiv. Biocon Biologics Canada Inc. <BR> xxv. Biocon Biologics Germany GmbH <BR> xxvi. Biocon Biologics France S.A.S <BR> xxvii. Biocon Biologics Spain, S.L. <BR> xxviii. Biocon Biologics Switzerland AG <BR> xxix. Biocon Biologics Belgium BV <BR> xxx. Biocon Biologics Finland OY <BR> xxxi. Biocon Generics Inc. <BR> xxxii. Biocon Biologics Morocco S.A.R.L.A.U <BR> xxxiii. Biocon Biologics Greece SINGLE MEMBER P.C <BR> xxxiv. Biocon Biologics South Africa (PTY) Ltd <BR> xxxv. Biocon Biologics (Thailand) Co. Ltd <BR> xxxvi. Biocon Biologics Philippines Inc <BR> xxxvii. Biocon Biologics Italy S.R.L <BR> xxxviii. Biocon Biologics Croatia LLC <BR> xxxix. Biocon Biologics Global PLC <BR> <BR> Biocon Limited and its subsidiaries are collectively referred to as ‘the Group’. In addition to the above, the consolidated financial results also include the financial results in respect of Biocon India Limited Employee Welfare Trust, Biocon Limited Employees Welfare Trust, Biocon Biologics Employees Welfare Trust and Syngene Employees Welfare Trust. The Company has also accounted for its share of interest in the joint venture i.e. NeoBiocon FZ-LLC (‘JV’) and share of investment in the associate i.e. Iatrica Inc., under the equity method. <BR> <BR> 4. During the quarter ended June 30, 2025, the Company raised funds by way of allotment of 136,363,635 Equity Shares of face value Rs. 5 each at a price of Rs. 330 per Equity Share under ‘Qualified Institutional Placement’ for an aggregate amount of Rs. 45,000 million, to meet certain financial commitments and / or debt obligations of the Company and its subsidiary, BBL and/ or for other purposes as mentioned in the Placement Document (‘PD’). <BR> <BR> Out of the above proceeds, on June 30, 2025, the Company acquired 1,125 outstanding Optionally Convertible Debentures (‘OCDs’) issued by BBL from Goldman Sachs India AIF Scheme- 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2 for an aggregate value of Rs. 16,980 million with a right to convert into equity shares or redeem at maturity. Further the company has issued a commitment letter effective July 1, 2025, committing to exercise its right to convert OCDs on maturity as per the terms of Subscription Agreement. <BR> <BR> Out of the above proceeds, during the quarter ended September 30, 2025, the Company has settled Commercial paper for an aggregate value of Rs. 5,988 million. <BR> <BR> 5. On April 23, 2025, the Board of Directors of Syngene recommended a final dividend of Rs. 1.25 per equity share <BR> of Rs. 10/-. This was approved by the shareholders of Syngene in the Annual General Meeting dated July 23, 2025, and has been distributed to the shareholders of Syngene during the quarter and half year ended September 30, 2025. <BR> <BR> 6. On May 08, 2025, the Board of Directors of the Company recommended a final dividend of Rs. 0.50 per equity <BR> share of Rs. 5/- each. This was approved by the shareholders of Company in the Annual General Meeting dated August 08, 2025, and has been distributed to the shareholders of the Company during the quarter and half year ended September 30, 2025. <BR> <BR> 7. In April 2024, BBL sold to Eris Lifesciences (‘Eris’) its business in relation to Metabolics, Oncology, and Critical Care products in India for a consideration of Rs. 12,420 million. Further, BBL signed a 10 year supply agreement with Eris. This resulted in a gain of Rs. 10,573 million after taking into account working capital and expenses incurred towards commercial collaboration and the same is disclosed under ‘’Other income” in the consolidated financial results for the year ended March 31, 2025. <BR> <BR> 8. Pursuant to amendment in The Finance Act, 2024, resulting in withdrawal of indexation benefit on Long-Term Capital Gain, the Company has written off Deferred Tax Asset created towards indexation benefit on Land amounting to Rs. 199 million. This is recorded under ‘Tax expense’ in the standalone and consolidated financial results for the quarter ended September 30, 2024 and year ended March 31, 2025. <BR> <BR> 9. The Group considers estimated shelf life of products, planned product discontinuances, price changes, ageing of inventory and introduction of competitive new products, to the extent each of these factors impact the Group’s business and markets, in determining the provision for slow moving, obsolete and other non-saleable inventory. Pursuant to the take-over of the Viatris's biosimilar business and completion of first anniversary since the exit from the transition service agreement, BBL re-assessed the provision for inventory of finished goods, raw material and semi-finished goods. This assessment resulted into a release of provision of Rs. 650 million in the year ended March 31, 2025 and the credit has been accounted for as a change in estimate within ‘Changes in inventories of traded goods, finished goods and work-in-progress’ and ‘Cost of materials consumed’ in the consolidated financial results. <BR> <BR> 10. During the year ended 31 March 2025, Syngene USA Inc. (wholly-owned subsidiary of Syngene) acquired biologics site in the USA fitted with multiple monoclonal antibody (mAbs) manufacturing lines from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.) and accounted for this transaction as an 'asset acquisition' under Ind AS 103. <BR> <BR> The costs incurred till March 31, 2025 eligible for capitalization were accumulated as Capital Work In Progress amounting to Rs. 2,981 million. An amount of Rs. 311 million has been capitalized as Land. These amounts include pre-transaction costs of Rs. 101 million. During the quarter and half year ended September 30 2025, additional pre-operating cost of Rs. 110 million and Rs. 165 million respectively, eligible for capitalisation has been accumulated under capital work in progress. <BR> <BR> 11. During the quarter and half year ended September 30, 2025, Syngene has written off Rs. 277 million as unrecoverable balances in receivables due to cumulative changes in foreign exchange rates. Consequent tax impact of Rs. 75 million is included within tax expense for the period. <BR> <BR> 12. During the quarter ended June 30, 2025, Syngene has been granted license for one of the drug substance production line and bonded warehouse license at biologics manufacturing facility, Bangalore, India which was acquired from Stelis Biopharma Limited and was recorded as capital work in progress in earlier years. Consequently, Rs. 3,438 million has been capitalized as property, plant and equipment which has resulted in a higher depreciation of Rs. 70 million and Rs. 106 million during the quarter and half year ended September 30, 2025. <BR> <BR> 13. Events after the reporting period: <BR> <BR> The Company has made early and full redemption of the 107,000 unlisted, secured, rated, redeemable, Non-convertible Debentures (NCDs) aggregating to Rs. 10,700 million subsequent to approval by its Board of Directors in their meeting held on October 01, 2025. <BR> <BR> 14. Exceptional items: <BR> <BR> a. During the year ended March 31, 2025, the Company sold 8,000,000 equity shares of Rs. 10 each of Syngene in the open market. The gain arising from sale of aforesaid equity shares amounting to Rs. 6,075 million has been recorded as an exceptional item in the standalone financial results. Consequent tax impact of Rs. 261 million is included within tax expense for the year. <BR> <BR> The sale proceeds arising from such sale of aforesaid equity shares net of amount transferred to Non-Controlling Interest account, has been accounted in other equity in the consolidated financial results since there is no loss of control. <BR> <BR> b. During the year ended March 31, 2024, one of the subsidiaries of BBL recorded provision for inventory for a product due to its low demand and consequentially lower probability of liquidation under the head ‘Exceptional Item’. Subsequently, during the quarter ended September 30, 2024 and year ended March 31, 2025, BBL liquidated such inventory amounting to Rs. 260 million and Rs. 885 million, respectively. Hence, the related provision has been reversed and reflected as an exceptional item in the consolidated financial results. Consequential tax impact of Rs. 38 million and Rs. 147 million is included within tax expense for the respective period/ year. <BR> <BR> c. BBL had written off the unamortized portion of debt raise cost amounting to Rs. 1,216 million pertaining to acquisition debt pursuant to pre-payment of such debt. This has been recorded as an expense in the consolidated statement of profit and loss for the year ended March 31, 2025. Consequent tax impact of Rs. 304 million is included within tax expense for the year. <BR> <BR> d. During the year ended March 31, 2025, BBL had received Rs. 2,518 million towards working capital under the existing arrangements, which was recorded at fair value of Rs. 1,382 million having regard to the timing and profitability of recovery. The resulting difference of Rs. 1,136 million is recorded as a gain in the consolidated financial results. Consequential tax impact of Rs. 284 million is included within tax expense. <BR> <BR> e. During the quarter ended September 30, 2025, one of the subsidiaries of BBL has reached settlement on a litigation matter with one of its customers for a settlement amount of Rs. 291 million and disclosed under “exceptional item”. Pursuant to settlement, the amount disclosed under “other expenses” pertaining to previous quarter has been re-classified to “exceptional item”. The associated tax impact of Rs. 73 million is included in the tax expense for the period. <BR> <BR> f. During year ended March 31, 2025, one of the subsidiary of Biocon Pharma Limited (‘BPL’), pursuant to the uncertainty in commercialization of product in certain territories, recorded an impairment of the carrying value of the intangible asset amounting to Rs. 86 million. <BR> <BR> <BR> g. During the year ended March 31, 2025, the Group invested Rs. 75 million in the equity shares issued by Indian Foundation for Quality Management ('IFQM') a Company incorporated under section 8 of the Companies Act, 2013. As at March 31, 2025, the Group has fair valued such investment and has recorded fair value charge of Rs. 75 million. <BR> <BR> h. During the year ended March 31, 2025, Syngene received its final claim of Rs. 320 million from the insurance company for the loss of fixed assets in fire incident on December 12, 2016. <BR> <BR> 2025-04-012025-09-30UnauditedStandalone112040000001951000000131550000006087000000452000000-13270000002519000000123400000067100000027380000001237400000078100000007810000004300000011200000015500000006260000000000626000000-57000000569000000668500000050.490.48000.490.48000Other Expenses1378000000Recovery of cost from co-development partners (net)0Other Expenses2744000000Recovery of cost from co-development partners (net)-60000009599000000821700000052000000005310000001460000000013285100000000201000000133052000000021200000001541850000009344000000847900000074800000001684400000030000000350000000331560000000152700000044027000000001982120000006685000000153146000000159831000000159831000000889000000000370000009260000004060000002240000000595000000215100000024501000000113900000073060000008445000000148500000034431000000354000000376000000106900000003623000000000383810000001982120000001. The unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 11, 2025. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. <BR> <BR> 2. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <BR> <BR> 3. The consolidated financial results include the financial results of the Company and its subsidiaries as follows: <BR> <BR> i. Syngene International Limited (‘’Syngene’’) <BR> ii. Biocon Biologics Limited (“BBL”) <BR> iii. Biocon Pharma Limited (“BPL”) <BR> iv. Biocon Academy <BR> v. Biocon SA <BR> vi. Biocon SDN. BHD <BR> vii. Biocon FZ LLC <BR> viii. Biocon Biologics International Limited (formerly known as Biocon Biologics UK Limited) <BR> ix. Biocon Pharma Inc. <BR> x. Biocon Biologics Healthcare Malaysia SDN. BHD <BR> xi. Biocon Pharma Ireland Limited <BR> xii. Biocon Pharma UK Limited <BR> xiii. Biocon Biosphere Limited <BR> xiv. Biocon Biologics Inc. <BR> xv. Biocon Biologics Do Brasil Ltda <BR> xvi. Biocon Biologics FZ-LLC <BR> xvii. Biocon Pharma Malta Limited <BR> xviii. Biocon Pharma Malta I Limited <BR> xix. Syngene USA Inc. <BR> xx. Syngene Manufacturing Solutions Limited <BR> xxi. Syngene Scientific Solutions Limited <BR> xxii. Biosimilar Collaborations Ireland Limited <BR> xxiii. Biocon Biologics UK PLC (formerly known as Biosimilars Newco Limited) <BR> xxiv. Biocon Biologics Canada Inc. <BR> xxv. Biocon Biologics Germany GmbH <BR> xxvi. Biocon Biologics France S.A.S <BR> xxvii. Biocon Biologics Spain, S.L. <BR> xxviii. Biocon Biologics Switzerland AG <BR> xxix. Biocon Biologics Belgium BV <BR> xxx. Biocon Biologics Finland OY <BR> xxxi. Biocon Generics Inc. <BR> xxxii. Biocon Biologics Morocco S.A.R.L.A.U <BR> xxxiii. Biocon Biologics Greece SINGLE MEMBER P.C <BR> xxxiv. Biocon Biologics South Africa (PTY) Ltd <BR> xxxv. Biocon Biologics (Thailand) Co. Ltd <BR> xxxvi. Biocon Biologics Philippines Inc <BR> xxxvii. Biocon Biologics Italy S.R.L <BR> xxxviii. Biocon Biologics Croatia LLC <BR> xxxix. Biocon Biologics Global PLC <BR> <BR> Biocon Limited and its subsidiaries are collectively referred to as ‘the Group’. In addition to the above, the consolidated financial results also include the financial results in respect of Biocon India Limited Employee Welfare Trust, Biocon Limited Employees Welfare Trust, Biocon Biologics Employees Welfare Trust and Syngene Employees Welfare Trust. The Company has also accounted for its share of interest in the joint venture i.e. NeoBiocon FZ-LLC (‘JV’) and share of investment in the associate i.e. Iatrica Inc., under the equity method. <BR> <BR> 4. During the quarter ended June 30, 2025, the Company raised funds by way of allotment of 136,363,635 Equity Shares of face value Rs. 5 each at a price of Rs. 330 per Equity Share under ‘Qualified Institutional Placement’ for an aggregate amount of Rs. 45,000 million, to meet certain financial commitments and / or debt obligations of the Company and its subsidiary, BBL and/ or for other purposes as mentioned in the Placement Document (‘PD’). <BR> <BR> Out of the above proceeds, on June 30, 2025, the Company acquired 1,125 outstanding Optionally Convertible Debentures (‘OCDs’) issued by BBL from Goldman Sachs India AIF Scheme- 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2 for an aggregate value of Rs. 16,980 million with a right to convert into equity shares or redeem at maturity. Further the company has issued a commitment letter effective July 1, 2025, committing to exercise its right to convert OCDs on maturity as per the terms of Subscription Agreement. <BR> <BR> Out of the above proceeds, during the quarter ended September 30, 2025, the Company has settled Commercial paper for an aggregate value of Rs. 5,988 million. <BR> <BR> 5. On April 23, 2025, the Board of Directors of Syngene recommended a final dividend of Rs. 1.25 per equity share <BR> of Rs. 10/-. This was approved by the shareholders of Syngene in the Annual General Meeting dated July 23, 2025, and has been distributed to the shareholders of Syngene during the quarter and half year ended September 30, 2025. <BR> <BR> 6. On May 08, 2025, the Board of Directors of the Company recommended a final dividend of Rs. 0.50 per equity <BR> share of Rs. 5/- each. This was approved by the shareholders of Company in the Annual General Meeting dated August 08, 2025, and has been distributed to the shareholders of the Company during the quarter and half year ended September 30, 2025. <BR> <BR> 7. In April 2024, BBL sold to Eris Lifesciences (‘Eris’) its business in relation to Metabolics, Oncology, and Critical Care products in India for a consideration of Rs. 12,420 million. Further, BBL signed a 10 year supply agreement with Eris. This resulted in a gain of Rs. 10,573 million after taking into account working capital and expenses incurred towards commercial collaboration and the same is disclosed under ‘’Other income” in the consolidated financial results for the year ended March 31, 2025. <BR> <BR> 8. Pursuant to amendment in The Finance Act, 2024, resulting in withdrawal of indexation benefit on Long-Term Capital Gain, the Company has written off Deferred Tax Asset created towards indexation benefit on Land amounting to Rs. 199 million. This is recorded under ‘Tax expense’ in the standalone and consolidated financial results for the quarter ended September 30, 2024 and year ended March 31, 2025. <BR> <BR> 9. The Group considers estimated shelf life of products, planned product discontinuances, price changes, ageing of inventory and introduction of competitive new products, to the extent each of these factors impact the Group’s business and markets, in determining the provision for slow moving, obsolete and other non-saleable inventory. Pursuant to the take-over of the Viatris's biosimilar business and completion of first anniversary since the exit from the transition service agreement, BBL re-assessed the provision for inventory of finished goods, raw material and semi-finished goods. This assessment resulted into a release of provision of Rs. 650 million in the year ended March 31, 2025 and the credit has been accounted for as a change in estimate within ‘Changes in inventories of traded goods, finished goods and work-in-progress’ and ‘Cost of materials consumed’ in the consolidated financial results. <BR> <BR> 10. During the year ended 31 March 2025, Syngene USA Inc. (wholly-owned subsidiary of Syngene) acquired biologics site in the USA fitted with multiple monoclonal antibody (mAbs) manufacturing lines from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.) and accounted for this transaction as an 'asset acquisition' under Ind AS 103. <BR> <BR> The costs incurred till March 31, 2025 eligible for capitalization were accumulated as Capital Work In Progress amounting to Rs. 2,981 million. An amount of Rs. 311 million has been capitalized as Land. These amounts include pre-transaction costs of Rs. 101 million. During the quarter and half year ended September 30 2025, additional pre-operating cost of Rs. 110 million and Rs. 165 million respectively, eligible for capitalisation has been accumulated under capital work in progress. <BR> <BR> 11. During the quarter and half year ended September 30, 2025, Syngene has written off Rs. 277 million as unrecoverable balances in receivables due to cumulative changes in foreign exchange rates. Consequent tax impact of Rs. 75 million is included within tax expense for the period. <BR> <BR> 12. During the quarter ended June 30, 2025, Syngene has been granted license for one of the drug substance production line and bonded warehouse license at biologics manufacturing facility, Bangalore, India which was acquired from Stelis Biopharma Limited and was recorded as capital work in progress in earlier years. Consequently, Rs. 3,438 million has been capitalized as property, plant and equipment which has resulted in a higher depreciation of Rs. 70 million and Rs. 106 million during the quarter and half year ended September 30, 2025. <BR> <BR> 13. Events after the reporting period: <BR> <BR> The Company has made early and full redemption of the 107,000 unlisted, secured, rated, redeemable, Non-convertible Debentures (NCDs) aggregating to Rs. 10,700 million subsequent to approval by its Board of Directors in their meeting held on October 01, 2025. <BR> <BR> 14. Exceptional items: <BR> <BR> a. During the year ended March 31, 2025, the Company sold 8,000,000 equity shares of Rs. 10 each of Syngene in the open market. The gain arising from sale of aforesaid equity shares amounting to Rs. 6,075 million has been recorded as an exceptional item in the standalone financial results. Consequent tax impact of Rs. 261 million is included within tax expense for the year. <BR> <BR> The sale proceeds arising from such sale of aforesaid equity shares net of amount transferred to Non-Controlling Interest account, has been accounted in other equity in the consolidated financial results since there is no loss of control. <BR> <BR> b. During the year ended March 31, 2024, one of the subsidiaries of BBL recorded provision for inventory for a product due to its low demand and consequentially lower probability of liquidation under the head ‘Exceptional Item’. Subsequently, during the quarter ended September 30, 2024 and year ended March 31, 2025, BBL liquidated such inventory amounting to Rs. 260 million and Rs. 885 million, respectively. Hence, the related provision has been reversed and reflected as an exceptional item in the consolidated financial results. Consequential tax impact of Rs. 38 million and Rs. 147 million is included within tax expense for the respective period/ year. <BR> <BR> c. BBL had written off the unamortized portion of debt raise cost amounting to Rs. 1,216 million pertaining to acquisition debt pursuant to pre-payment of such debt. This has been recorded as an expense in the consolidated statement of profit and loss for the year ended March 31, 2025. Consequent tax impact of Rs. 304 million is included within tax expense for the year. <BR> <BR> d. During the year ended March 31, 2025, BBL had received Rs. 2,518 million towards working capital under the existing arrangements, which was recorded at fair value of Rs. 1,382 million having regard to the timing and profitability of recovery. The resulting difference of Rs. 1,136 million is recorded as a gain in the consolidated financial results. Consequential tax impact of Rs. 284 million is included within tax expense. <BR> <BR> e. During the quarter ended September 30, 2025, one of the subsidiaries of BBL has reached settlement on a litigation matter with one of its customers for a settlement amount of Rs. 291 million and disclosed under “exceptional item”. Pursuant to settlement, the amount disclosed under “other expenses” pertaining to previous quarter has been re-classified to “exceptional item”. The associated tax impact of Rs. 73 million is included in the tax expense for the period. <BR> <BR> f. During year ended March 31, 2025, one of the subsidiary of Biocon Pharma Limited (‘BPL’), pursuant to the uncertainty in commercialization of product in certain territories, recorded an impairment of the carrying value of the intangible asset amounting to Rs. 86 million. <BR> <BR> <BR> g. During the year ended March 31, 2025, the Group invested Rs. 75 million in the equity shares issued by Indian Foundation for Quality Management ('IFQM') a Company incorporated under section 8 of the Companies Act, 2013. As at March 31, 2025, the Group has fair valued such investment and has recorded fair value charge of Rs. 75 million. <BR> <BR> h. During the year ended March 31, 2025, Syngene received its final claim of Rs. 320 million from the insurance company for the loss of fixed assets in fire incident on December 12, 2016. <BR> <BR> 1234000000-9810000009530000000118000000000039500000000067100000000-330000000002640000000194000000-12310000000-3340000000-430000000679000000146000000000011000000001350000000000169800000000000010800000000008000000000000000906000000000264000000670000000-7253000000-25896000000004500000000000049000000004416000000150000006680000004300000000-63600000038884000000143380000001100000014349000000249500000016844000000Items that will not be reclassified to profit or loss6300000063000000Items that will not be reclassified to profit or loss-27000000-270000009000000-10000000Items that will be reclassified to profit or loss-61000000-61000000Items that will be reclassified to profit or loss-54000000-54000000-16000000-140000009000000-57000000Biocon Limited******Biocon Biologics Limited******SubsidiarySale of goods or services2000000000No remarks by the Audit Committee82030000000Biocon Limited******Biocon Biologics Limited******SubsidiarySale of goods or services350000000No remarks by the Audit Committee15360000000Biocon Limited******Biocon Biologics Limited******SubsidiaryAny other transactionESOP cost recovery230000000No remarks by the Audit Committee2300000000Biocon Limited******Biocon Biologics Limited******SubsidiaryAny other transactionOther expenses recovery249800000No remarks by the Audit Committee2676000000Biocon Limited******Biocon Biologics Limited******SubsidiarySale of goods or services125000000No remarks by the Audit Committee4218000000Biocon Limited******Biocon Biologics Limited******SubsidiarySale of goods or services470000000No remarks by the Audit Committee16363000000Biocon Limited******Biocon Biologics Limited******SubsidiaryAny other transactionExpense for research and development services300420000No remarks by the Audit Committee137000000Biocon Limited******Biocon SDN BHD******Step down subsidiaryAny other transactionESOP cost recovery50000000No remarks by the Audit Committee138000000Biocon Limited******Biocon SDN BHD******Step down subsidiarySale of goods or services20000000No remarks by the Audit Committee282000000Biocon Limited******Biocon Biologics UK Limited******Step down subsidiarySale of goods or services10000000No remarks by the Audit Committee121000000Biocon Limited******Biocon Biologics UK Limited******Step down subsidiaryAny other transactionESOP cost recovery10000000No remarks by the Audit Committee000Biocon Limited******Syngene International Limited******SubsidiaryPurchase of goods or services20000000No remarks by the Audit Committee107000000Biocon Limited******Syngene International Limited******SubsidiaryAny other transactionExpenses reimbursement payable10000000No remarks by the Audit Committee163000000Biocon Limited******Syngene International Limited******SubsidiarySale of goods or services329000000No remarks by the Audit Committee13238000000Biocon Limited******Syngene International Limited******SubsidiarySale of goods or services316000000No remarks by the Audit Committee13200000000Biocon Limited******Bicara Therapeutics Inc.******Enterprise in which relative to a director of the Company is proprietorSale of goods or services200000000No remarks by the Audit Committee2900000000Biocon Limited******Neo Biocon FZ LLC******AssociateSale of goods or services5000000No remarks by the Audit Committee000Biocon Limited******Neo Biocon FZ LLC******AssociatePurchase of goods or services5000000No remarks by the Audit Committee000Biocon Limited******Immuneel Therapeutics Private Limited******Enterprise in which a director of the Company is a member of board of directorsSale of goods or services5000000No remarks by the Audit Committee000Biocon Limited******Biocon Foundation******Trust in which a director is a trusteeAny other transactionCSR Related activities35000000No remarks by the Audit Committee1410000000Biocon Limited******Jeeves******Enterprise in which relative to a director of the Company is proprietorPurchase of goods or services40000000No remarks by the Audit Committee1021000000Biocon Limited******Mazumdar Shaw Medical Foundation******Enterprise in which a director of the Company is a member of board of directorsPurchase of goods or services2000000No remarks by the Audit Committee000Biocon Limited******Biocon Pharma Limited******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee181967000000Biocon Limited******Biocon Pharma Limited******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee903000000Biocon Limited******Biocon Pharma Limited******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee6541000000Biocon Limited******Biocon Pharma Limited******Wholly owned subsidiaryAny other transactionESOP cost recovery0No remarks by the Audit Committee1451000000Biocon Limited******Biocon Pharma Limited******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee1896000000Biocon Limited******Biocon Pharma Limited******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee821000000Biocon Limited******Biocon Pharma Limited******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee187000000Biocon Limited******Biocon Pharma Limited******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee4001000000Biocon Limited******Biocon Pharma Inc******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee16325000000Biocon Limited******Biocon Pharma Inc******Wholly owned subsidiaryAny other transactionESOP cost recovery0No remarks by the Audit Committee1943000000Biocon Limited******Biocon FZ LLC******Wholly owned subsidiaryPurchase of goods or services0No remarks by the Audit Committee1918000000Biocon Limited******Biocon Biosphere Limited******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee22127000000Biocon Limited******Biocon Biosphere Limited******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee2233000000Biocon Limited******Biocon Biosphere Limited******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee5900000000Biocon Limited******Biocon Biosphere Limited******Wholly owned subsidiaryPurchase of goods or services0No remarks by the Audit Committee47300000000Biocon Limited******Biocon Biosphere Limited******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee6800000000Biocon Limited******Biocon Biosphere Limited******Wholly owned subsidiaryInterest received0No remarks by the Audit Committee2671000000Biocon Limited******Biocon Biosphere Limited******Wholly owned subsidiaryAny other transactionESOP cost recovery0No remarks by the Audit Committee215000000Biocon Limited******Biocon Biosphere Limited******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee337000000Biocon Limited******Biocon Biosphere Limited******Wholly owned subsidiaryLoan0No remarks by the Audit Committee92400000000Loan0.072On demandUnsecuredDevelopment of new manufacturing facilityBiocon Limited******Biocon Biosphere Limited******Wholly owned subsidiaryAny other transactionConversion of loan into OCRPS0No remarks by the Audit Committee92400000053890000006313000000Biocon Limited******Biocon Pharma Malta I Limited******Wholly owned subsidiaryAny other transactionESOP cost recovery0No remarks by the Audit Committee1077000000Biocon Limited******Biocon Pharma Inc******Wholly owned subsidiaryAny other transactionOther expenses recovery0No remarks by the Audit Committee13000000Biocon Limited******Biocon Biosphere Limited******Wholly owned subsidiaryAny other transactionGuarantee outstanding0No remarks by the Audit Committee042710000004293330000Biocon Pharma Limited******Biocon Pharma UK Limited******Wholly owned subsidiaryPurchase of goods or services0No remarks by the Audit Committee4300000000Biocon Pharma Limited******Biocon Pharma UK Limited******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee19800000000Biocon Pharma Limited******Biocon Pharma Malta I Limited******Wholly owned subsidiaryPurchase of goods or services0No remarks by the Audit Committee9500000000Biocon Pharma Limited******Biocon Pharma Malta I Limited******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee7900000000Biocon Biosphere Limited******Biocon Biologics Limited******Fellow subsidiaryPurchase of goods or services20000000No remarks by the Audit Committee1400000000Biocon Biosphere Limited******Biocon Biologics Limited******Fellow subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee0150000007000000Biocon Pharma Limited******Biocon Biosphere Limited******Fellow subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee04000000112000000Biocon Pharma Limited******Biocon Biologics Limited******Fellow subsidiaryPurchase of goods or services2000000000No remarks by the Audit Committee22000000000Biocon Pharma Limited******Biocon Biologics Limited******Fellow subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee0857000000982000000Biocon Pharma Limited******Biocon Pharma Inc******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee149700000000Biocon Pharma Limited******Biocon Generics Inc******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee1700000000Biocon Limited******Biocon Generics Inc******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee14386000000Biocon Limited******Biocon Generics Inc******Wholly owned subsidiaryAny other transactionESOP cost recovery0No remarks by the Audit Committee215000000Biocon Limited******Biocon Generics Inc******Wholly owned subsidiaryAny other transactionCharges for issue of corporate guarantee0No remarks by the Audit Committee1873000017090000001727730000Biocon Limited******Biocon Generics Inc******Wholly owned subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee0442000000624840000Biocon Limited******Biocon Biologics Limited******SubsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee012011000001262320000Biocon Limited******Biocon Biologics Limited******SubsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee023584000001973600000Biocon Limited******Biocon SDN BHD******Step down subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee02500001000000Biocon Limited******Biocon SDN BHD******Step down subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee030000007000000Biocon Limited******Biocon Biologics UK Limited******Step down subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee000Biocon Limited******Biocon Biologics UK Limited******Step down subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee010000000Biocon Limited******Syngene International Limited******SubsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee0210000004000000Biocon Limited******Syngene International Limited******SubsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee0141000000102460000Biocon Limited******Bicara Therapeutics Inc.******Enterprise in which relative to a director of the Company is proprietorAny other transactionTrade and other receivables0No remarks by the Audit Committee01200000012100000Biocon Limited******Biocon Foundation******Trust in which a director is a trusteeAny other transactionTrade and other receivables0No remarks by the Audit Committee03200000018000000Biocon Limited******Biocon Pharma Limited******Wholly owned subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee0340000000359000000Biocon Limited******Biocon Pharma Limited******Wholly owned subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee01355000000319000000Biocon Limited******Biocon Pharma Inc******Wholly owned subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee05500000057000000Biocon Limited******Biocon Pharma Inc******Wholly owned subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee053000000243000000Biocon Limited******Biocon FZ LLC******Wholly owned subsidiaryAny other transactionESOP cost recovery0No remarks by the Audit Committee216000000Biocon Limited******Biocon FZ LLC******Wholly owned subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee05400000051000000Biocon Limited******Biocon FZ LLC******Wholly owned subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee000Biocon Limited******Biocon Academy******Wholly owned subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee01300000013000000Biocon Limited******Biocon Biosphere Limited******Wholly owned subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee0263000000747630000Biocon Limited******Biocon Biosphere Limited******Wholly owned subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee0432000000788000000Biocon Limited******Biocon Pharma UK Limited******Wholly owned subsidiaryAny other transactionESOP cost recovery0No remarks by the Audit Committee215000000Biocon Limited******Biocon Pharma UK Limited******Wholly owned subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee010000000Biocon Limited******Biocon Pharma Malta I Limited******Wholly owned subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee040000004630000Biocon Pharma Limited******Biocon Pharma UK Limited******Wholly owned subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee013200000089000000Biocon Pharma Limited******Biocon Pharma UK Limited******Wholly owned subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee0178000000229000000Biocon Pharma Limited******Biocon Pharma Ireland Limited******Wholly owned subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee003000000Biocon Pharma Limited******Biocon Pharma Ireland Limited******Wholly owned subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee000Biocon Pharma Limited******Biocon Pharma Malta Limited******Wholly owned subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee000Biocon Pharma Limited******Biocon Pharma Malta Limited******Wholly owned subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee000Biocon Pharma Limited******Biocon Pharma Malta I Limited******Wholly owned subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee05700000091000000Biocon Pharma Limited******Biocon Pharma Malta I Limited******Wholly owned subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee097000000157000000Biocon Pharma Limited******Biocon Pharma Inc******Wholly owned subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee0806000000855000000Biocon Pharma Limited******Biocon Pharma Inc******Wholly owned subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee048370000002548000000Biocon Pharma Limited******Biocon Foundation******Trust in which a director is a trusteeAny other transactionCSR12000000No remarks by the Audit Committee700000000Biocon Pharma Limited******Biocon FZ LLC******Fellow subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee050000005000000Biocon Pharma Limited******Biocon FZ LLC******Fellow subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee020000002000000Biocon Pharma Limited******Biocon Generics Inc******Wholly owned subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee04400000042230000Biocon Pharma UK Limited******Biocon Pharma Ireland Limited******Fellow subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee000Biocon Pharma UK Limited******Biocon Pharma Malta I Limited******Fellow subsidiarySale of goods or services40000000No remarks by the Audit Committee1427000000Biocon Pharma UK Limited******Biocon Pharma Malta I Limited******Fellow subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee050000003000000Biocon Pharma UK Limited******Biocon Pharma Malta Limited******Fellow subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee000Biocon Pharma Malta I Limited******Biocon SA******Fellow subsidiaryLoan0No remarks by the Audit Committee04400000044000000Biocon Pharma Inc******Biocon SA******Fellow subsidiaryLoan1299600000No remarks by the Audit Committee012996700001299670000Biocon Pharma Inc******Biocon SA******Fellow subsidiaryInterest paid20000000No remarks by the Audit Committee968000000Biocon Pharma Inc******Biocon Generics Inc******Fellow subsidiaryPurchase of goods or services1500000000No remarks by the Audit Committee44952000000Biocon Pharma Inc******Biocon Generics Inc******Fellow subsidiaryAny other transactionTrade and other payables0No remarks by the Audit Committee012200000096000000Biocon Pharma Inc******Biocon Generics Inc******Fellow subsidiaryAny other transactionTrade and other receivables0No remarks by the Audit Committee01600000023000000Syngene International Limited******Kiran Mazumdar Shaw******Non-Executive Chairperson Any other transactionSitting fees & Commission 9500000No remarks by the Audit Committee396000000Syngene International Limited******Professor Catherine Rosenberg******Non-Executive Director Any other transactionSitting fees & Commission9000000No remarks by the Audit Committee458000000Syngene International Limited******Bicara Therapeutics Inc.******Enterprise in which a Director of the Company is a member of the Board of DirectorsSale of goods or services937000000No remarks by the Audit Committee583000000-138000000-445290000Syngene International Limited******Biocon Biologics Limited******Fellow subsidiarySale of goods or services23000000No remarks by the Audit Committee483000099000000137110000Syngene International Limited******Biocon Biologics UK Limited******Fellow subsidiarySale of goods or services73000000No remarks by the Audit Committee23790000260000004990000Syngene International Limited******Biocon Pharma Limited******Fellow subsidiarySale of goods or services43000000No remarks by the Audit Committee46000015000000340000Syngene International Limited******Biocon SDN BHD******Fellow subsidiarySale of goods or services7000000No remarks by the Audit Committee060000000Syngene International Limited******Biosimilar collaborations Ireland******Fellow subsidiarySale of goods or services4000000No remarks by the Audit Committee020000000Syngene International Limited******BIOSIMILARS NEWCO LIMITED******Fellow subsidiarySale of goods or services10000000No remarks by the Audit Committee53600000140000Syngene International Limited******Cage Therapeutics Incorporation******Enterprise in which a Director of the Company is a member of the Board of DirectorsSale of goods or services5720000No remarks by the Audit Committee88000030000000Syngene International Limited******Immuneel Therapeutics Private Limited******Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services6000000No remarks by the Audit Committee432000020000007870000Syngene International Limited******Narayana Hrudayalaya Limited******Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services10000000No remarks by the Audit Committee000Syngene International Limited******Syngene Scientific solutions Ltd.******Wholly owned subsidiarySale of goods or services40370000No remarks by the Audit Committee403700003800000068000000Syngene International Limited******Therapoma Inc******Enterprise in which a Director of the Company is a member of the Board of Directors Sale of goods or services1000000No remarks by the Audit Committee3900000250000Syngene International Limited******Third Arc Bio******Enterprise in which a Director of the Company has significant influenceSale of goods or services400000000No remarks by the Audit Committee110170000090540000Syngene International Limited******Biocon Biologics Limited******Fellow subsidiarySale of goods or services370000000No remarks by the Audit Committee16530000000Syngene International Limited******Syngene Manufacturing solutions Ltd.******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee5000000Syngene International Limited******Syngene Scientific solutions Ltd.******Wholly owned subsidiarySale of goods or services0No remarks by the Audit Committee5000000Syngene International Limited******Biocon Biologics Limited******Fellow subsidiarySale of goods or services100000000No remarks by the Audit Committee3636000000Syngene International Limited******Syngene Scientific solutions Ltd.******Wholly owned subsidiaryAny other transactionExpenses reimbursement receivable117190000No remarks by the Audit Committee11719000000Syngene International Limited******Syngene USA Inc.******Wholly owned subsidiaryAny other transactionExpenses reimbursement receivable64310000No remarks by the Audit Committee64310000130000000201350000Syngene International Limited******Therapoma Inc******Enterprise in which a Director of the Company is a member of the Board of Directors Purchase of goods or services12000000No remarks by the Audit Committee000Syngene International Limited******Biocon Biologics Limited******Fellow subsidiaryAny other transactionExpenses reimbursement receivable15000000No remarks by the Audit Committee443000000Syngene International Limited******Syngene Scientific solutions Ltd.******Wholly owned subsidiaryAny other transactionRemittance of trade receivable realized0No remarks by the Audit Committee00-165010000Syngene International Limited******Syngene Scientific solutions Ltd.******Wholly owned subsidiaryPurchase of goods or services357620000No remarks by the Audit Committee35762000000Syngene International Limited******Syngene Scientific solutions Ltd.******Wholly owned subsidiaryPurchase of goods or services11300000No remarks by the Audit Committee1130000000Syngene International Limited******Biocon Biologics Limited******Fellow subsidiaryPurchase of goods or services159000000No remarks by the Audit Committee35420000-38000000-46000000Syngene International Limited******Biocon Pharma Limited******Fellow subsidiaryAny other transactionExpenses reimbursement payable10000000No remarks by the Audit Committee000Syngene International Limited******Immuneel Therapeutics Pvt Ltd.******Enterprise in which a Director of the Company is a member of the Board of Directors Any other transactionExpenses reimbursement payable10000000No remarks by the Audit Committee000Syngene International Limited******Biocon Biologics Limited******Fellow subsidiaryPurchase of goods or services10000000No remarks by the Audit Committee000Syngene International Limited******Syngene Scientific solutions Ltd.******Wholly owned subsidiaryPurchase of goods or services0No remarks by the Audit Committee0-1340000000Syngene International Limited******Biocon Academy******Fellow subsidiaryAny other transactionCSR15000000No remarks by the Audit Committee119500000-130000Syngene International Limited******Biocon Academy******Fellow subsidiaryAny other transactionOther1000000No remarks by the Audit Committee105000000Syngene International Limited******Biocon Foundation******Trust in which a director is a trusteeAny other transactionCSR110000000No remarks by the Audit Committee4805000030000000Syngene International Limited******Syngene USA Inc.******Wholly owned subsidiaryPurchase of goods or services537730000No remarks by the Audit Committee537730000-48000000-157080000Syngene International Limited******Narayana Hrudayalaya Limited******Enterprise in which a Director of the Company is a member of the Board of Directors Purchase of goods or services5000000No remarks by the Audit Committee24600000-50000Syngene International Limited******SOTC Travel Limited******Enterprise in which a Director of the Company is a member of the Board of Directors of Holding CompanyPurchase of goods or services60000000No remarks by the Audit Committee47660000-5000000-7860000Syngene International Limited******Thomas Cook (India) Limited******Enterprise in which a Director of the Company is a member of the Board of Directors Purchase of goods or services10000000No remarks by the Audit Committee000Syngene International Limited******Jeeves******Enterprise in which a member of the Promoter Group is a Partner Any other transactionLaundry service5000000No remarks by the Audit Committee24500000-140000Biocon Biologics Limited******Biocon SDN BHD******SubsidiarySale of goods or services3550000000No remarks by the Audit Committee440560000-17949000022430000Biocon Biologics Limited******Biocon SDN BHD******SubsidiaryPurchase of goods or services2500000000No remarks by the Audit Committee62692000000Biocon Biologics Limited******Biocon SDN BHD******SubsidiaryAny other transactionGuarantee given0No remarks by the Audit Committee0-854300000-888400000Biocon Biologics Limited******Biocon Biologics UK Limited******SubsidiarySale of goods or services19486600000No remarks by the Audit Committee075405600003006160000Biocon Biologics Limited******Biosimilar Collaborations Ireland Limited******SubsidiarySale of goods or services21296600000No remarks by the Audit Committee399092000039324100004260700000Biocon Biologics Limited******Biocon Biologics Global Plc******SubsidiarySale of goods or services250000000No remarks by the Audit Committee38960000171520000211080000Biocon Biologics Limited******Biocon Biologics Global Plc******SubsidiaryAny other transactionGuarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BCIL, BUK and BNCL0No remarks by the Audit Committee0-68343000000-78179200000Biocon Biologics Limited******Biosimilars Newco Limited******SubsidiarySale of goods or services36533300000No remarks by the Audit Committee1032445000047070000006206130000Biocon Biologics Limited******Biosimilars Newco Limited******SubsidiaryPurchase of goods or services1260000000No remarks by the Audit Committee6443000000Biocon Biologics Limited******Biosimilars Newco Limited******SubsidiaryAny other transactionGuarantee given towards Debt obtained by BNCL, jointly/severally by BBL, BSDN, BCIL, BUK and BBGP0No remarks by the Audit Committee0-27336600000-28428800000Biocon Biologics Limited******Biocon Biologics Germany******SubsidiarySale of goods or services530000000No remarks by the Audit Committee20000020000Biocon Biologics Limited******Jeeves******Enterprise in which relative to a director of the Company is proprietorPurchase of goods or services100000000No remarks by the Audit Committee14390000-350000-440000Biocon Biologics Limited******Narayana Hrudayalaya Limited******Enterprise in which a director of the Company is a member of board of directorsSale of goods or services0No remarks by the Audit Committee0890000890000Biocon Biologics Limited******Biocon Academy******Fellow subsidiaryPurchase of goods or services80000000No remarks by the Audit Committee200000001289000037920000Biocon Biologics Limited******Biocon Foundation******Fellow subsidiaryPurchase of goods or services100000000No remarks by the Audit Committee2150000000Biocon Biologics Limited******Biocon Biologics Inc, US******SubsidiarySale of goods or services250000000No remarks by the Audit Committee0-30910000-29260000Biocon Biologics Limited******Biocon Biologics Inc, US******SubsidiaryPurchase of goods or services0No remarks by the Audit Committee000Biocon Biologics Limited******Biocon Biologics Canada Inc******SubsidiarySale of goods or services100000000No remarks by the Audit Committee025000002500000Biocon Biologics Limited******Biocon Biologics Philippines******SubsidiarySale of goods or services0No remarks by the Audit Committee0600000600000Biocon Biologics Limited******Viatris Group******SubsidiaryAny other transactionContingent consideration payable0No remarks by the Audit Committee0-8970000000-8597000000Biocon Biologics UK Limited******Biocon Biologics Inc, US******SubsidiaryPurchase of goods or services0No remarks by the Audit Committee0-30000-30000Biocon Biologics UK Limited******Biocon Biologics Brasil Ltda******SubsidiaryPurchase of goods or services500000000No remarks by the Audit Committee010690000118790000Biocon Biologics UK Limited******Biocon Biologics FZ-LLC, UAE******SubsidiaryPurchase of goods or services500000000No remarks by the Audit Committee0119000016530000Biocon Biologics UK Limited******Biocon Biologics Canada Inc******SubsidiaryPurchase of goods or services0No remarks by the Audit Committee01000020000Biocon Biologics UK Limited******Biocon Biologics (Thailand) Co., Ltd.******SubsidiaryPurchase of goods or services0No remarks by the Audit Committee018600001930000Biocon Biologics UK Limited******Biocon Biologics Morocco S.R.L******SubsidiaryPurchase of goods or services0No remarks by the Audit Committee07939000082560000Biocon Biologics UK Limited******Biocon Biologics South Africa (Pty) Ltd.******SubsidiaryPurchase of goods or services0No remarks by the Audit Committee01420000014760000Biocon Biologics UK Limited******Biocon Biologics Philippines******SubsidiaryPurchase of goods or services0No remarks by the Audit Committee02556000026900000Biocon Biologics UK Limited******Biocon SDN BHD******SubsidiaryPurchase of goods or services0No remarks by the Audit Committee0-70000-70000Biocon Biologics UK Limited******Biocon Biologics Healthcare SDN BHD******SubsidiaryPurchase of goods or services0No remarks by the Audit Committee0360000440000Biocon Biologics UK Limited******Biocon Biologics Global Plc******SubsidiarySale of goods or services530000000No remarks by the Audit Committee375300003269000072490000Biocon Biologics UK Limited******Biocon Biologics Global Plc******SubsidiaryAny other transactionGuarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BCIL, BUK and BNCL0No remarks by the Audit Committee0-68343000000-78179200000Biocon Biologics UK Limited******Biosimilar Collaborations Ireland Limited******SubsidiarySale of goods or services3350000000No remarks by the Audit Committee01752620000756500000Biocon Biologics UK Limited******Biosimilar Collaborations Ireland Limited******SubsidiaryPurchase of goods or services0No remarks by the Audit Committee000Biocon Biologics UK Limited******Biosimilars Newco Limited******SubsidiarySale of goods or services31156660000No remarks by the Audit Committee31166000034428000002545260000Biocon Biologics UK Limited******Biosimilars Newco Limited******SubsidiaryPurchase of goods or services940000000No remarks by the Audit Committee000Biocon Biologics UK Limited******Biosimilars Newco Limited******SubsidiaryAny other transactionGuarantee given towards Debt obtained by BNCL, jointly/severally by BBL, BSDN, BCIL, BUK and BBGP0No remarks by the Audit Committee0-27337600000-28428800000Biocon Biologics UK Limited******Biocon Biologics Belgium BV******SubsidiaryPurchase of goods or services0No remarks by the Audit Committee08000090000Biocon Biologics UK Limited******Biocon Biologics Italy******SubsidiaryPurchase of goods or services0No remarks by the Audit Committee016200001680000Biocon SDN BHD******Biocon Biologics FZ-LLC, UAE******Fellow subsidiaryPurchase of goods or services200000000No remarks by the Audit Committee5720000-127590000-5890000Biocon SDN BHD******Biocon Biologics Inc, US******Fellow subsidiaryPurchase of goods or services0No remarks by the Audit Committee0-1076500000Biocon SDN BHD******Biocon Biologics Healthcare SDN BHD******Fellow subsidiaryPurchase of goods or services0No remarks by the Audit Committee020100002200000Biocon SDN BHD******Biosimilar Collaborations Ireland Limited******Fellow subsidiarySale of goods or services2310000000No remarks by the Audit Committee726540000-673860000-328150000Biocon SDN BHD******Biosimilar Collaborations Ireland Limited******Fellow subsidiaryPurchase of goods or services860000000No remarks by the Audit Committee988000000Biocon SDN BHD******Biocon Biologics Global Plc******Fellow subsidiarySale of goods or services14240000000No remarks by the Audit Committee3468130000290740000-1545410000Biocon SDN BHD******Biocon Biologics Global Plc******Fellow subsidiaryAny other transactionGuarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BCIL, BUK and BNCL0No remarks by the Audit Committee0-68343000000-78179200000Biocon SDN BHD******Biosimilars Newco Limited******Fellow subsidiarySale of goods or services15070000000No remarks by the Audit Committee1493270000-2572280000-2850630000Biocon SDN BHD******Biosimilars Newco Limited******Fellow subsidiaryAny other transactionGuarantee given towards Debt obtained by BNCL, jointly/severally by BBL, BSDN, BCIL, BUK and BBGP0No remarks by the Audit Committee0-27337600000-28428800000Biosimilars Newco Limited******Biocon Biologics Canada Inc******Fellow subsidiarySale of goods or services2140000000No remarks by the Audit Committee194820000-1926660000-2340800000Biosimilars Newco Limited******Biocon Biologics Inc, US******Fellow subsidiarySale of goods or services32750000000No remarks by the Audit Committee113010800006257220000-2336350000Biosimilars Newco Limited******Biocon Biologics Inc, US******Fellow subsidiaryPurchase of goods or services2610000000No remarks by the Audit Committee10581000000Biosimilars Newco Limited******Biocon Biologics Brasil Ltda******Fellow subsidiaryPurchase of goods or services690000000No remarks by the Audit Committee1862200000-102360000Biosimilars Newco Limited******Biocon Biologics FZ-LLC, UAE******Fellow subsidiaryPurchase of goods or services640000000No remarks by the Audit Committee891400000-68630000Biosimilars Newco Limited******Biocon Biologics (Thailand) Co., Ltd.******Fellow subsidiaryPurchase of goods or services100000000No remarks by the Audit Committee30530000-29070000-61500000Biosimilars Newco Limited******Biocon Biologics Morocco S.R.L******Fellow subsidiaryPurchase of goods or services320000000No remarks by the Audit Committee91080000-105040000-23380000Biosimilars Newco Limited******Biocon Biologics South Africa (Pty) Ltd.******Fellow subsidiaryPurchase of goods or services130000000No remarks by the Audit Committee17230000-18710000-24380000Biosimilars Newco Limited******Biocon Biologics Philippines******Fellow subsidiaryPurchase of goods or services150000000No remarks by the Audit Committee63700000-42530000-75760000Biosimilars Newco Limited******Biocon Biologics Germany******Fellow subsidiaryPurchase of goods or services480000000No remarks by the Audit Committee5261000090850000321510000Biosimilars Newco Limited******Biocon Biologics Germany******Fellow subsidiarySale of goods or services1460000000No remarks by the Audit Committee29678000000Biosimilars Newco Limited******Biocon Biologics France******Fellow subsidiarySale of goods or services1840000000No remarks by the Audit Committee318420000497550000875340000Biosimilars Newco Limited******Biocon Biologics Spain******Fellow subsidiarySale of goods or services670000000No remarks by the Audit Committee22070000-89910000-120410000Biosimilars Newco Limited******Biocon Biologics Finland******Fellow subsidiaryPurchase of goods or services230000000No remarks by the Audit Committee8500000-24740000-32930000Biosimilars Newco Limited******Biocon Biologics Belgium BV******Fellow subsidiaryPurchase of goods or services230000000No remarks by the Audit Committee9390000-89600001080000Biosimilars Newco Limited******Biocon Biologics Greece******Fellow subsidiaryPurchase of goods or services270000000No remarks by the Audit Committee51800004751000060120000Biosimilars Newco Limited******Biocon Biologics Greece******Fellow subsidiarySale of goods or services550000000No remarks by the Audit Committee1706000000Biosimilars Newco Limited******Biocon Biologics Swiss******Fellow subsidiaryPurchase of goods or services440000000No remarks by the Audit Committee35170000-3780000-61120000Biosimilars Newco Limited******Biocon Biologics Swiss******Fellow subsidiarySale of goods or services470000000No remarks by the Audit Committee1670000000Biosimilars Newco Limited******Biocon Biologics Italy******Fellow subsidiaryPurchase of goods or services100000000No remarks by the Audit Committee829200002750000-51470000Biosimilars Newco Limited******Biocon Biologics Croatia******Fellow subsidiaryPurchase of goods or services50000000No remarks by the Audit Committee36650000-4230000-4540000Biosimilars Newco Limited******Biocon Biologics Global Plc******Fellow subsidiaryPurchase of goods or services100000000No remarks by the Audit Committee05445200001493650000Biosimilars Newco Limited******Biocon Biologics Global Plc******Fellow subsidiarySale of goods or services900000000No remarks by the Audit Committee21149000000Biosimilars Newco Limited******Biocon Biologics Global Plc******Fellow subsidiaryPurchase of goods or services6000000000No remarks by the Audit Committee268622000000Biosimilars Newco Limited******Biocon Biologics Global Plc******Fellow subsidiaryAny other transactionGuarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BCIL, BUK and BNCL0No remarks by the Audit Committee0-68343000000-78179200000Biosimilar Collaborations Ireland Limited******Biocon Biologics Inc, US******Fellow subsidiarySale of goods or services1320000000No remarks by the Audit Committee303920000204710000-399380000Biosimilar Collaborations Ireland Limited******Biocon Biologics Inc, US******Fellow subsidiaryPurchase of goods or services20000000No remarks by the Audit Committee000Biosimilar Collaborations Ireland Limited******Biocon Biologics Brasil Ltda******Fellow subsidiarySale of goods or services1530000000No remarks by the Audit Committee002010000Biosimilar Collaborations Ireland Limited******Biocon Biologics FZ-LLC, UAE******Fellow subsidiaryPurchase of goods or services140000000No remarks by the Audit Committee0380000400000Biosimilar Collaborations Ireland Limited******Biocon Biologics Canada Inc******Fellow subsidiarySale of goods or services1810000000No remarks by the Audit Committee512820000-96100000444040000Biosimilar Collaborations Ireland Limited******Biocon Biologics Canada Inc******Fellow subsidiaryPurchase of goods or services50000000No remarks by the Audit Committee000Biosimilar Collaborations Ireland Limited******Biocon Biologics (Thailand) Co., Ltd.******Fellow subsidiaryPurchase of goods or services100000000No remarks by the Audit Committee1980000-2230000-4320000Biosimilar Collaborations Ireland Limited******Biocon Biologics Morocco S.R.L******Fellow subsidiaryPurchase of goods or services320000000No remarks by the Audit Committee60600000-17380000-79780000Biosimilar Collaborations Ireland Limited******Biocon Biologics Philippines******Fellow subsidiarySale of goods or services590000000No remarks by the Audit Committee09100001120000Biosimilar Collaborations Ireland Limited******Biocon Biologics Germany******Fellow subsidiarySale of goods or services15733330000No remarks by the Audit Committee551247000018507300004029140000Biosimilar Collaborations Ireland Limited******Biocon Biologics Germany******Fellow subsidiaryPurchase of goods or services280000000No remarks by the Audit Committee000Biosimilar Collaborations Ireland Limited******Biocon Biologics France******Fellow subsidiarySale of goods or services6290000000No remarks by the Audit Committee2247950000458960000-521100000Biosimilar Collaborations Ireland Limited******Biocon Biologics Spain******Fellow subsidiarySale of goods or services1320000000No remarks by the Audit Committee227620000436820000454820000Biosimilar Collaborations Ireland Limited******Biocon Biologics Finland******Fellow subsidiaryPurchase of goods or services230000000No remarks by the Audit Committee251000002355000023380000Biosimilar Collaborations Ireland Limited******Biocon Biologics Belgium BV******Fellow subsidiaryPurchase of goods or services380000000No remarks by the Audit Committee117460000-23720000-55690000Biosimilar Collaborations Ireland Limited******Biocon Biologics Greece******Fellow subsidiaryPurchase of goods or services270000000No remarks by the Audit Committee5930000-225940000-110120000Biosimilar Collaborations Ireland Limited******Biocon Biologics Greece******Fellow subsidiarySale of goods or services1150000000No remarks by the Audit Committee54713000000Biosimilar Collaborations Ireland Limited******Biocon Biologics Swiss******Fellow subsidiarySale of goods or services580000000No remarks by the Audit Committee3241000043440000124010000Biosimilar Collaborations Ireland Limited******Biocon Biologics Italy******Fellow subsidiaryPurchase of goods or services100000000No remarks by the Audit Committee016000000-4970000Biosimilar Collaborations Ireland Limited******Biocon Biologics Croatia******Fellow subsidiaryPurchase of goods or services50000000No remarks by the Audit Committee257300003120000-3000000Biosimilar Collaborations Ireland Limited******Biocon Biologics Croatia******Fellow subsidiarySale of goods or services740000000No remarks by the Audit Committee000Biosimilar Collaborations Ireland Limited******Biocon Biologics Global Plc******Fellow subsidiarySale of goods or services100000000No remarks by the Audit Committee375300003207000072490000Biosimilar Collaborations Ireland Limited******Biocon Biologics Global Plc******Fellow subsidiaryAny other transactionGuarantee given towards Senior Secured Notes isuued by BBGP, jointly and severally by BBL, BSDN, BCIL, BUK and BNCL0No remarks by the Audit Committee0-68343000000-78179200000Biosimilar Collaborations Ireland Limited******Biosimilars Newco Limited******Fellow subsidiarySale of goods or services2250000000No remarks by the Audit Committee24670000000Biosimilar Collaborations Ireland Limited******Biosimilars Newco Limited******Fellow subsidiaryPurchase of goods or services7150000000No remarks by the Audit Committee3244460000-6227700000-15542180000Biosimilar Collaborations Ireland Limited******Biosimilars Newco Limited******Fellow subsidiaryAny other transactionGuarantee given towards Debt obtained by BNCL, jointly/severally by BBL, BSDN, BCIL, BUK and BBGP0No remarks by the Audit Committee0-27337600000-28428800000Biosimilar Collaborations Ireland Limited******Viatris Group******Enterprise in which a director of the Company is a member of board of directorsPurchase of goods or services0No remarks by the Audit Committee000Biocon Biologics Inc, US******Biocon Biologics Global Plc******Fellow subsidiaryPurchase of goods or services14110000000No remarks by the Audit Committee3595740000-258050000483880000Biocon Biologics France******Viatris Sante S.A.S******Enterprise in which a director of the Company is a member of board of directorsPurchase of goods or services200000000No remarks by the Audit Committee5531000090000055310000Biocon Biologics Global Plc******Biosimilars Newco Limited******Fellow subsidiaryLoan0No remarks by the Audit Committee06768858000070390420000Biocon Biologics Global Plc******Biosimilars Newco Limited******Fellow subsidiaryInterest received0No remarks by the Audit Committee023957600002675330000Biocon Biologics Global Plc******Biosimilars Newco Limited******Fellow subsidiaryAny other transactionGuarantee given towards Debt obtained by BNCL, jointly/severally by BBL, BSDN, BCIL, BUK and BBGP0No remarks by the Audit Committee0-27337600000-28428800000Biocon Limited******Kiran Mazumdar Shaw******Key Management PersonnelRemuneration0No remarks by the Audit Committee2719000000Biocon Limited******Ravi Mazumdar******Non-Executive DirectorAny other transactionSitting fees and commission0No remarks by the Audit Committee39100000065814520000QIP2025-06-19450000000002025-09-30trueIndia Ratings & Research Private LimitedfalseNot ApplicableNot ApplicableNot ApplicableRajesh U. ShanoyCompany Secretary and Compliance OfficerBangaluru2025-11-11Purchase of outstanding optionally convertible debentures issued by our Subsidiary, Biocon Biologics Limited from Goldman Sachs India AIF Scheme – 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2Not Applicable1710000000016980460000169804600000The Placement document states, if the actual utilization towards the objects is lower than the proposed deployment, such balance will be used for general corporate purposes. Accordingly, the lower utilization of INR 119.54 Mn towards object no. 1 on account of exchange rate fluctuation is added to General Corporate Purposes.Repayment, pre-payment or redemption, in full or in part, of certain outstanding financial instruments issued by our Company, borrowings availed by our Company, and/or meeting other financial commitments of our CompanyNot Applicable271500000002715000000059876800000General Corporate PurposesNot Applicable5000000016954000000The Placement document states, if the actual utilization towards the objects is lower than the proposed deployment, such balance will be used for general corporate purposes. Accordingly, the lower utilization of INR 119.54 Mn towards object no. 1 on account of exchange rate fluctuation is added to General Corporate Purposes.Issue related expensesNot Applicable7000000007000000006840100000